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ABSTRACT 
Hexamethylene tetramine (HMT) is a food additive, currently only permitted in EU for use in Provolone cheese. 
The maximum permitted level is 25 mg/kg residual amount, expressed as formaldehyde, the break down product 
of HMT under acidic conditions. HMT has been previously evaluated by the Joint Expert Committee on Food 
Additives (JECFA, 1974) who established an ADI of 0.15 mg/kg bw/day based on a reproductive study with a 
NOEL of 15 mg/kg bw/day. Due to the limitations in the database the Panel could not identify a critical study 
and therefore to derive an ADI. However, the Panel noted that the exposure to formaldehyde from HMT of high 
level consumers of Provolone cheese equalled 18 µg formaldehyde/kg bw/day in adults and could be as high as 
87 µg formaldehyde/kg bw/day in children according to a theoretical conservative assumption that all ripened 
cheese consumed was Provolone cheese. Considering the estimated exposure from the very limited permitted 
use, the toxicological database on HMT, the data from use of HMT therapeutically, the available oral toxicity 
and toxicokinetic data of formaldehyde and the magnitude of the potential effect on intracellular formaldehyde 
levels arising from this use of HMT, the Panel concluded that the use of HMT in Provolone cheese at the MPL 
of 25 mg/kg residual amount, expressed as formaldehyde, would not be of safety concern. However the Panel 
considered that any increase in the permitted uses of HMT or increases in the MPL of 25 mg /kg residual 
amount, expressed as formaldehyde would need detailed assessment which might require new toxicity data as 
well as use levels and/or an evaluation of its impact on formaldehyde levels in vivo. 
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SUMMARY 
The ANS Panel was not provided with a newly submitted dossier and based its evaluation on previous 
evaluation, reviews and additional literature that became available since then. An additional source of 
information was the registration dossier provided by industry for HMT under the REACH Regulation 
1907/2006, published by the European Chemicals Agency (ECHA, 2011). The Panel noted that not all 
original studies on which previous evaluations or reviews were based were available for re-evaluation 
by the Panel. 
Specifications for HMT have been defined in  Commission Regulation (EU) No 231/2012 and by 
JECFA (2006).  HMT is described as colourless or white crystalline powder. The purity is specified as 
not less than 99% anhydrous. Under acidic aqueous conditions HMT can yield formaldehyde and 
ammonia. 
HMT (E 239) is currently only permitted for use in Provolone cheese at a maximum level of 25 mg/kg 
residual  amount,  expressed  as  formaldehyde.  The  formaldehyde  released  from  HMT  under  acidic 
conditions or in cheese can react with proteins. 
HMT has been previously evaluated by the Joint Expert Committee on Food Additives (JECFA) in 
1962, 1965, 1967, 1972 and 1974 (JECFA, 1962, 1965, 1967, 1972 and 1974). JECFA established an 
ADI of 0.15 mg/kg bw/day based on a reproductive study with a NOEL of 15 mg/kg bw/day (JECFA, 
1974). HMT has not been directly evaluated as a food additive by the Scientific Committee on Food 
(SCF). In 1977, the SCF referred to HMT during its evaluation of the use of formaldehyde in grana 
padano  cheese,  since  HMT  decomposes  to  form  formaldehyde  under  acidic  conditions  or  in  the 
presence of proteins (SCF, 1977). More recently, TemaNord in 2002 (TemaNord, 2002), the United 
States Environmental Protection Agency (EPA) in 2006 (EPA, 2006) and the Federal Institute for 
Occupational Safety and Health (BAuA, Germany) in 2008 (BAuA, 2008)  reviewed the safety of 
HMT. 
Under acidic conditions, HMT is converted to formaldehyde, which in turn would be converted into 
formic  acid.    Overall,  both  in  animal  and  human  studies,  formaldehyde  is  rapidly  absorbed  and 
converted to formic acid. The rate of oxidation of formaldehyde to formic acid was comparable in all 
animal species, with a half-life of only 1 minute. The elimination half-life of formic acid is reported to 
vary from 55 minutes in animals to 90 minutes in humans and can be excreted via the kidneys or 
further oxidised to CO2 and water (JECFA, 1962, 1965, 1972, 1974; BAuA, 2008).  In humans, about 
88% of the administered oral dose of 1 g HMT was absorbed within 12 hours and excreted mostly 
unchanged (about 82% of recovery) in the urine in 24 hours. The maximum serum concentration (35.2 
mg/L) after a single dose was achieved within 1 hour and the mean elimination half-life in blood was 
reported  to  be  4.3  hours.  Approximately  10-20%  of  an  oral  dose  of  HMT  is  converted  to 
formaldehyde. HMT can pass the placenta and is detectable in breast milk of breastfeeding women; 
however, no accumulation was reported. Formaldehyde formation from HMT was dependent on pH , 
formaldehyde generation prior to absorption would be relevant following oral ingestion as the pH of 
the stomach is acidic and has been estimated as 10-20% of the dose. Further down the gastrointestinal 
tract, the pH is neutral with nearly no generation of formaldehyde. HMT can also be converted into 
formaldehyde in urine and the rate of conversion was pH dependent (BAuA, 2008). 
Results from animal experiments and limited data in humans indicate that HMT is of very low to 
moderate acute toxicity. 
There  is  limited  information  available  on  the  subchronic  toxicity  of  HMT.    None  of  the  studies 
provided data on haematology and clinical chemistry; data on histopathology were limited. However, 
body weight gain, food consumption, survival, organ weights, gross pathology and histopathology 
were generally unaffected following exposure to HMT. The only treatment related clinical observation 
in studies with rats was a yellow staining of the perineal hair in some cases and decreased body weight 
gain or weight loss in a 15 weeks study in rabbits.  Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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With regards to the genotoxicity, HMT was weakly positive in bacterial gene mutation assays and in 
an indicator tests in yeast  and at high doses in tests for chromosomal aberrations and sister chromatid 
exchanges in  mammalian cells in vitro (BAuA,  2008). In vivo, negative results were  obtained in 
chromosomal aberration tests in mouse bone marrow by the oral route and in the dominant lethal test 
in mice by i.p. administration, indicating that the genotoxic activity elicited by HMT in vitro is not 
systemically expressed in vivo. The Panel noted that HMT may be partially converted in the stomach 
into formaldehyde which, at high doses, is genotoxic in vivo at the site of first contact. In this respect 
the Panel noted that HMT used as food additive breaks down into formaldehyde during cheese-making 
and storage, and that in situ formed formaldehyde largely reacts with amino groups of milk proteins. 
Thus, the exposure to formaldehyde resulting from the use of HMT as food additive is expected to be 
negligible,  much  lower  than  resulting  from  other  authorized  uses  or  from  normal  mammalian 
metabolism (878-1310 mg/kg bw/day assuming a half -life of 1-1.5 min; EFSA, 2014). Overall, the 
Panel  concluded  that  the  proposed  use  of  HMT  as  food  additive  does  not  raise  concern  for 
genotoxicity. 
Available information on the chronic toxicity of HMT was limited. None of the studies provided data 
on haematology and clinical chemistry. Body weight gain, food consumption, organ weights, gross 
pathology and histopathology were unaffected following exposure to HMT. However, survival rates 
and growth were significantly decreased in a study in CTM mice treated with 12.5 g HMT/kg bw/day 
for 30  weeks.  The  only  treatment  related  clinical  observation  in  studies with  rats  was  occasional 
yellow staining of the perineal hair. Overall, HMT was not carcinogenic in experimental animals 
treated at doses up to 2.5 g HMT/kg bw/day (Brendel, 1964; Natvig et al., 1971; Della Porta, 1968; 
Lijinsky and Taylor, 1977). For all the studies, the NOAELs for HMT corresponded to the highest 
dose tested.  The BAuA (2008) evaluation reported that the existing long-term/carcinogenicity studies 
on HMT were not in line with the current guidelines on carcinogenicity and/or combined chronic 
toxicity/carcinogenicity.  However,  the  data  submitted  were  considered  useful  in  assessing  the 
carcinogenic potential of HMT. In addition, considering the negative results from in vivo genotoxicity 
testing, BAuA concluded that HMT was not considered as carcinogenic for experimental animals 
(BAuA,  2008).  The  BAuA  evaluation  (2008)  also  reported  that  one  valid  cancer  study  with 
formaldehyde administered via drinking water to rats did not show an increased tumour incidence in 
any organ (Til et al., 1989). The Panel concluded that the formation of formaldehyde from HMT 
should not be of concern with regards to carcinogenicity. The relevant long-term studies using oral 
administration of formaldehyde have been discussed in the EFSA evaluation in 2006 (EFSA, 2006). 
A large set of data have been described on the reproductive and developmental toxicity of HMT in 
rats, dogs, and human. Overall, the information available is limited, due to the use of low numbers of 
animals, limited number of reproductive and developmental parameters recorded, and teratogenicity 
not properly assessed. However, data available indicated that HMT did not present the potential to 
induce adverse effects on the fertility in rats.  Both the EPA (EPA, 2006) and the BAuA evaluations 
(BAuA, 2008) considered a NOAEL of 1.5-2.5 g HMT/kg bw/day for reproductive toxicity in rats, 
based on the study by Della Porta et al. (1970). With regards to developmental toxicity, in both rats 
and beagle dogs adverse developmental effects observed during the postnatal period were preweaning 
mortality and postnatal growth retardation. The BAuA evaluation (BAuA, 2008) reported NOAEL 
values for developmental toxicity for rats (Natvig et al., 1971) and dogs (Hurni and Ohder, 1973) of 
100 mg HMT/kg bw/day (the highest dose) and 15 mg HMT/kg bw/day, respectively. However, the 
EPA (2006) evaluation concluded that there are many inconsistencies on the results of the dog study, 
since the effects were not consistent with the dose levels, and no details have been provided to clarify 
these inconstancies. Therefore, the EPA (2006) did not take into account the dog study for their risk 
assessment (only the rat studies by Della Porta, 1970 and Berglund, 1966). In humans, the study by 
Furness  et  al.  (1974)  showed  that  no  treatment-related  abnormalities  during  the  pregnancy  or the 
development of the children had been reported. Negative findings were also found in the study by 
Siffel and Czeisel (1995). However, in the surveillance study by Briggs et al. (1994), 3.8% (of 209 
newborn whose mothers had been treated with HMT during the first trimester) showed birth defects 
(BAuA, 2008). The BAuA evaluation (2008) concluded that, overall, all the studies reported did not 
sufficiently meet the requirements for a sound risk assessment evaluation with respect to reproductive Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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and  developmental  toxicity.  The  Panel  concluded  that  despite  limitations  in  the  database  on 
reproductive and developmental toxicity, the available data were sufficient for evaluating the single 
permitted  use  and  use  levels.  The  EFSA  Opinion  (EFSA,  2006)  on  formaldehyde  reported  that 
formaldehyde  does  not  affect  reproduction  or  gestational  developmental  parameters  (IPCS,  1989; 
CICAD, 2002). 
No adverse effects have been reported in patients receiving HMT for long-term prophylaxis or therapy 
as urinary antibacterial-antiseptic substance at dose levels of 2 to 4 g/day (corresponding to 28 to 57 
mg/kg bw/day) for up to 4 weeks (corresponding to a NOAEL of 57 mg/kg bw/day). However, with a 
higher dose of 8 g/day (corresponding to 114 mg/kg bw/day) over 3 to 4 weeks clinical symptoms 
such as bladder irritation, painful and frequent micturition, albuminuria and haematuria were reported 
in some individuals. With regards to the use of HMT as a drug in humans there is no information 
available on the formation of tumours in the urinary tract or in other organs or tissues (BAuA, 2008).  
In  humans,  skin  sensitizing  properties  of HMT  have  been reported.  Following skin contact  acute 
dermatitis  was  the  main  symptom.  Other  reports  described  a  number  of  cases  in  which  allergic 
symptoms of the respiratory system were also reported following HMT exposure. However, in all 
cases  exposure  to  other  chemicals  occurred  simultaneously,  therefore  the  induction  of  specific 
respiratory hypersensitivity by HMT cannot be clearly demonstrated. Regarding data available on 
effects of HMT on human following occupational exposure (by inhalation or skin contact), human 
data  available  do  not  provide  any  conclusive  information  on  the  association  between  HMT 
occupational exposure and cancer in humans, since toxic effects in humans at the workplace have only 
been  reported  after  repeated  exposure  to  mixtures  of  several  compounds  rather  than  HMT  alone 
(BAuA, 2008).  
The estimated mean exposure to HMT (expressed as formaldehyde) via consumption of Provolone 
cheese was low for the total population: on average 0.3 µg formaldehyde/kg bw/day. For consumers 
only of Provolone cheese the mean exposure ranged from 5 µg formaldehyde/kg bw/day in toddlers up 
to 20 µg formaldehyde/kg bw/day in children (95
th percentiles: 18 µg formaldehyde/kg bw/day for 
adults). According to a theoretical conservative assumption  that all ripened cheese consumed was 
Provolone  cheese,  the  highest  estimated  exposure,  using  the  95
th  percentile  of  consumers  only 
combined with the MPL, equalled 87 µg formaldehyde/kg bw/day in children. 
The Panel concluded that due to the limitations in the toxicological database a critical study could not 
be identified and therefore it was not possible to derive an ADI. The exposure to formaldehyde from 
HMT of high level consumers (95
th) of Provolone cheese equalled 18 µg formaldehyde/kg bw/day in 
adults and could be as high as 87 µg formaldehyde/kg bw/day in 3-9 year old children according to a 
theoretical conservative assumption  that all ripened cheese consumed was Provolone cheese. These 
exposures were around 1000 fold lower than formaldehyde exposure corresponding to the human 
therapeutic doses of 57 mg HMT/kg bw/day not associated with adverse effects in humans. Based on 
the:  
  estimated exposures,  
  consideration of the overall toxicological database on HMT,  
  oral toxicity and toxicokinetic data of formaldehyde,  
  the magnitude of the potential effect on intracellular formaldehyde levels arising from this use 
of HMT  
The Panel concluded that the use of HMT in Provolone cheese at the MPL of 25 mg/kg residual 
amount, expressed as formaldehyde, would not be of safety concern. Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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However the Panel considered that any increase in the permitted uses of HMT or increases in the MPL 
of 25 mg /kg residual amount, expressed as formaldehyde would require detailed assessment which 
might  require  new  toxicity  data  as  well  as  use  levels  and/or  an  evaluation  of  its  impact  on 
formaldehyde levels in vivo. Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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BACKGROUND AS PROVIDED BY EUROPEAN COMMISSION 
Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives 
requires that food additives are subject to a safety evaluation by the European Food Safety Authority 
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food 
additives must be kept under continuous observation and must be re-evaluated by EFSA. 
For this purpose, a programme for the re-evaluation of food additives that were already permitted in 
the European Union before 20 January 2009 has been set up under Regulation (EU) No 257/2010
4. 
This Regulation also foresees that food additives are re -evaluated whenever necessary in light of 
changing conditions of use and new scientific information. For efficiency and practical purposes, the 
re-evaluation should, as far as possible, be conducted by group of food additives according to the main 
functional class to which they belong. 
The order of priorities for the re-evaluation of the currently approved food additives should be set on 
the basis of the following criteria: the time since the last evaluation of a food additive by the Scientific 
Committee on Food (SCF) or by EFSA, the availability of new scientific evidence, the extent of use of 
a food additive in food and the human exposure to the food additive  taking also into account the 
outcome of the Report from the Commission on Dietary Food Additive Intake in the EU
5 of 2001. The 
report  “Food  additives  in  Europe  2000
6” submitted by the Nordic Council of Ministers to the 
Commission, provides additional information for the prioritisation of additives for the re-evaluation. 
As colours were among the first additives to be evaluated, these food additives should be re-evaluated 
with the highest priority. 
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised 
food additives. However, as a result of the adoption of Regulation (EU) 257/2010 the 2003 Terms of 
Reference are replaced by those below. 
TERMS OF REFERENCE AS PROVIDED BY EUROPEAN COMMISSION 
The Commission asks the European Food Safety Authority to re-evaluate the safety of food additives 
already permitted in the Union before 2009 and to issue scientific opinions on these additives, taking 
especially into account the priorities, procedures and deadlines that are enshrined in Regulation (EU) 
No  257/2010  of  25  March  2010  setting  up  a  programme  for  the  re-evaluation  of  approved  food 
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the 
Council on food additives. 
 
                                                       
4  OJL 80, 26.03.2010, p19 
5  COM(2001) 542 final. 
6  Food Additives in Europe 2000, Status of safety assessments of food additives presently permitted in the EU, Nordic  
  Council of Ministers, TemaNord 2002:560. Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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ASSESSMENT 
1.  Introduction 
The present opinion deals with the re-evaluation of the safety of hexamethylene tetramine (HMT) (E 
239) when used as food additive. 
HMT  is  a  food  preservative  authorised  to  be  used  only  in  Provolone  cheese,  in  accordance  with 
Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives, at a 
maximum level of 25 mg/kg residual amount, expressed as formaldehyde (EFSA, 2006). 
HMT has been previously evaluated by the Joint Expert Committee on Food Additives (JECFA) in 
1962, 1965, 1967, 1972 and 1974 (JECFA, 1962, 1965, 1967, 1972 and 1974). JECFA established an 
ADI of 0.15 mg HMT/kg bw/day based on a reproductive study with a NOEL of 15 mg HMT/kg 
bw/day (JECFA, 1974). HMT has not been directly evaluated as a food additive by the Scientific 
Committee on Food (SCF). In 1977, the SCF referred to HMT during its evaluation of the use of 
formaldehyde in grana padano cheese, since HMT can decompose to form formaldehyde under acidic 
conditions or in the presence of proteins (SCF, 1977). 
The Panel on Food Additives and Nutrient Sources added to Food (ANS) was not provided with a 
newly submitted dossier and based its evaluation on previous  evaluations, reviews  and additional 
literature that became available. No data was submitted following a public call for data.
7 
2.  Technical data 
2.1.  Identity of the substances 
HMT (E 239) is a preservative, its molecular formula is C6H12N4 and its molecular weight is 140.19 
g/mol.  The CAS Registry Number is 100-97-0 and EINECS number is 202-905-8. The chemical 
name is 1,3,5,7-tetraazatricyclo [3.3.1.1
3,7]-decane. 
The structural formula of HMT is given in Figure 1: 
 
Figure 1:   Structural formula of HMT 
HMT is a colourless or white crystalline powder.  HMT sublimes at temperatures > 250°C (Haynes 
and Lide, 2010). It is very soluble in water (667 g/L (BAuA, 2008)), soluble in ethanol, acetone and 
chloroform and slightly soluble in diethyl ether and benzene (Haynes and Lide, 2010).  The partition 
coefficient is -4.15 (BAuA, 2008). It has over 30 synonyms; some of the most common ones are 
formin, hexamine, urotropin and methenamine. 
Up to six molecules of formaldehyde can be released from each molecule of HMT. 
                                                       
7  Call for scientific data on food additives permitted in the EU and belonging to the functional classes of preservatives and 
  antioxidants. Published: 23 November 2009 and modified on 5 February 2010. Available from:  
  http://www.efsa.europa.eu/en/dataclosed/call/ans091123a.htm 
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2.2.  Specifications 
Specifications have been defined by  Commission Regulation (EU) No 231/2012
8, JECFA, 2006c; 
TemaNord, 2002)
9  and by the JECFA (2006, this is the compendium of JECFA specifications 
incorporating the original HMT specification defined in 1973).  Metals and arsenic specifications were 
revised at the 63
rd JECFA (2005). These are detailed in Table 1. 
Table 1:   Specifications for HMT (E 239) according to Commission Regulation (EU) No 231/2012 
and by JECFA (JECFA, 2006) 
  Commission  Regulation  (EU)  No 
231/2012  JECFA (2006)
  
Description  Colourless or white crystalline powder 
Nearly  odourless,  colourless 
lustrous  crystals,  or  white 
crystalline powder 
Assay  Not  less  than  99%  on  the  anhydrous 
basis 
Not  less  than  99.0%  on  the 
dried basis 
Identification     
Solubility  -  Freely  soluble  in  water  and 
soluble in ethanol 
Formaldehyde 
test  
Positive 
Heat a 1 in 10 solution of the 
sample  with  dilute  sulphuric 
acid  TS.    Formaldehyde  is 
liberated,  recognizable  by  its 
odour and by its darkening of 
paper  moistened  with  silver 
ammonium nitrate TS. 
Ammonia test  Passes test 
Sublimation 
point  Approximately 260°C  - 
Purity     
Loss on drying 
No  more  than  0.5%  after  drying  at 
105°C  in  vacuum  over  P2O5  for two 
hours 
No more than 2.0% over P 2O5 
for four hours 
Sulphated ash  Not more than 0.05% 
No more than 0.05%   
Test 2 g of the sample (method 
I) 
                                                       
8  Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down specifications for food additives listed in  
  Annexes II and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012,  
  p 1-295 
9  Commission Directive 2008/84/EC of 27 August 2008 laying down specific purity criteria on food additives other than  
colours and sweeteners. OJ L 253, 20.9.2008, p.1 Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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  Commission  Regulation  (EU)  No 
231/2012  JECFA (2006)
  
Sulphate  Not  more  than  0.005%  expressed  as 
SO4  - 
Chlorides   Not more than 0.005% expressed as Cl  - 
Ammonium salts  Not detectable 
Colour  comparison  with  a 
reference  standard  should  not 
be darker.
a 
Arsenic  Not more than 3 mg/kg  - 
Lead  Not more than 2 mg/kg  No more than 2 mg/kg 
Mercury  Not more than 1 mg/kg  - 
(a):  Add 1 mL of Nessler‟s reagent TS to 10 mL of a 5% solution of the sample.  The mixture 
should not be darker than a mixture of 1 mL of the reagent in 10 mL of water. 
The Panel noted that the European Pharmacopeia  for use of HMT as a pharmaceutical contains a limit 
for free formaldehyde in HMT (50 mg/kg).  
There are a number of differences between the EU and JECFA specifications; 
  The „loss on drying‟ is no more than 0.5% (2 hours) and not more than 2.0% (4 hours) in the 
EU and JECFA specifications respectively.   
  No limits for sulphate and chloride content in the JECFA specification are provided. 
2.3.  Manufacturing process 
A process for hexamethylenetetramine production was described by Meissner et al. (1954). In this 
process, HMT is produced by a direct addition reaction between formaldehyde and ammonia in the 
gaseous phase. The reaction slurry obtained after the addition reaction is subjected to a continuous 
centrifugation in which the crystals are separated, washed and dried. In the process crystallised HMT 
is produced continuously (purity 98 %). 
To separate the very small amount of side products formed in the reaction, the mother liquor from the 
reactor is passed over adsorption filters and continuously purified. The process is further detailed in 
the paper cited above.  
Other production processes have been described in literature (Smolin & Rapoport, 1959; Dan et al.  
2011; Kovac Kralj; 2013; Taghdiri & Zamani, 2013). 
2.4.  Methods of analysis in food 
Several methods have been reported in the literature for the detection of HMT in food. A bioassay uses 
Staphylococcus  aureus,  a  yoghurt  producing  lactic  acid  organism  and  2,3,5-triphenyltetrazolium 
chloride as indicator of bacterial growth (Kotter, 1959), steam distillation has been used followed by 
colour  reaction  (Dumitrescu,  1975)  and  chromatographic  methods  (Kovacs  and  Denker,  1962; 
Sandoval, 1960). Infrared (IR) spectroscopy has been used for the detection (Paseiro Losada et al., 
1989).  Colorimetric  methods  for  the  determination  of  hexamethylene  tetramine  amongst  other 
preservatives have been also reported (Engst, 1969). One of the most recent methods reported in the Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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literature is a simultaneous determination of methylene blue, HMT and resorcinol in pharmaceutical 
formulations by first derivative UV spectroscopy (Onur and Acar, 1992). Potentiometric titration has 
been used for the determination of HMT in the presence of large quantities of urea, formaldehyde and 
ammonium hydroxide (Ganatra et al., 1998). 
2.5.  Reaction and fate in food 
HMT is unstable under acidic conditions. 
Hutschenreuter (1956), when studying the fate of HMT in fish marinades, found that under acidic 
conditions  HMT  decomposes  with  the  formation  of  formaldehyde  and  ammonia  and  that  the 
decomposition of HMT is enhanced when protein material (in casu fish proteins) is present. This is 
stated  to  be  due  to  the  rapid  reaction  of  formaldehyde  with  amino  acids  (such  as  histidine  or 
tryptophan) present in proteins.  
In a review by Restani and Galli (1991) on the oral toxicity of formaldehyde it is stated that HMT 
liberates formaldehyde in the stomach under acidic conditions. HMT decomposes gradually yielding 
ammonia and formaldehyde which are stated to be normal body constituents. It is further indicated that 
formaldehyde is a very reactive compound and that it reacts with different macromolecules such as 
proteins and nucleic acids. 
Formaldehyde in food systems such as cheese subsequently reacts and can form a variety of products 
such  as  spinacine  (Restani  and  Galli,  1992).  The  Panel  noted  that  the  latter  paper  contains 
determinations  of  tolerance  level  of  spinacine  in  cheese  which  is  not  supported  by  experimental 
evidence. 
2.6.  Case of need and proposed uses 
Maximum Permitted Levels (MPLs) of HMT (E 239) have been defined in the Annex II of Regulation 
(EC) No 1333/2008
10 on food additives for use in foodstuffs. 
Currently, HMT (E 239) is an authorised food additive in the EU in Provolone cheese at a maximum 
residual allowed use level of 25 mg/kg residual amount, expressed as formaldehyde.  
Table 2 summarises foods that are permitted to contain 4-HR (E 586) and the corresponding MPLs as 
set by Annex II of Regulation (EC) No 1333/2008. 
Table 2:   MPL  of  HMT  (E  239)  in  foods  according  to  the  Annex  II  of  Regulation  (EC) 
No 1333/2008 
Category 
number 
Food  restrictions/exception  Maximum  level  (mg/L  or  mg/kg  as 
appropriate) 
1.7.2  Ripened 
cheese 
only Provolone cheese  25  mg/kg  residual  amount,  expressed  as 
formaldehyde 
Commission Regulation No 10/2011 on plastic materials and articles intended to come into contact 
with food
11 also set a specific migration limit of 15 mg/kg for formaldehyde. HMT  (E 239) can be 
used  outside  the  EU  as  a  pre servative  in  other  cheeses  (ripened  cheeses,  including  rind)  if 
technologically justified and only within the functions and limit specified (JECFA, 2006). 
                                                       
10    Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives. OJ L 354, 31.12.2008,  
     p. 16 
11   Commission Regulation (EU) No 10/2011 of 14 January on plastic materials and articles intended to come into contact  
    with food. OJ L 12/1, p 1-89 Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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2.6.1.  Actual and reported level of use of HMT (E 239)  
Most food additives in the EU are authorised at a specific MPL. However, a food additive may be used 
at a lower level than the MPL. In the framework of Regulation (EC) No 1333/2008 on food additives 
and of Regulation (EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA 
issued a public call for usage level and concentration data in food and beverages on HMT (E 239) in 
March 2013 with deadline November 2013. Data requested included present use and use patterns (i.e. 
which food categories and subcategories, proportion of food within categories/subcategories in which 
it  is  used,  actual  use  levels  (typical  and  maximum  use  levels)  and  concentration  data 
(analytical/monitoring data). 
However, no data on HMT (E 239) were received during this call. The below exposure assessment is 
therefore only based on the MPL of HMT (25 mg/kg) expressed as residual formaldehyde levels. 
2.7.  Information on existing authorisations and evaluations 
HMT (E 239) has been evaluated by JECFA in 1962, 1965, 1967, 1972 and 1974 (JECFA, 1962, 
1965,  1967,  1972  and  1974).  JECFA  established  an  ADI  of  0.15  mg/kg  bw/day  based  on  a 
reproductive study with a NOEL of 15 mg/kg bw/day (JECFA, 1974). 
HMT (E 239) has not been directly evaluated as a food additive by the SCF. In 1977, the SCF referred 
to HMT during the evaluation of the use of formaldehyde in grana padano cheese, since HMT can 
decompose to form formaldehyde under acidic conditions or in the presence of proteins (SCF, 1977). 
HMT (E 239) has also been reviewed by TemaNord (TemaNord, 2002). TemaNord reported that HMT 
(E 239) was positive in several mutagenicity tests and noted one incidence of increased tumours in one 
of the long-term studies and recommended a re-evaluation of HMT (E 239). 
In 2006, the United States Environmental Protection Agency (EPA) reassessed HMT when used as an 
inert ingredient in pesticide formulations (EPA, 2006). The EPA concluded that no harmful effects 
would result from the exposure to HMT when used as an inert ingredient in pesticide formulations also 
taking into account dietary exposure and all other non-occupational sources of pesticide exposure 
(EPA, 2006). 
Formaldehyde in drinking-water has been considered in the Guidelines for Drinking-water Quality 
(WHO, 2008).  Concentrations up to 30 μg/L have been found in ozonated drinking-water. It was not 
considered  necessary  though  to  set  a  formal  guideline  value  for  formaldehyde  in  view  of  the 
significant difference between the expected concentrations of formaldehyde in drinking-water and the 
tolerable concentration (WHO, 2008). 
The  European  Food  Safety  Authority  (EFSA)  issued  two  opinions  on  the  safety  in  use  of 
formaldehyde for poultry (EFSA, 2004) and used as a preservative during the manufacture of food 
additives (EFSA, 2006). The toxicity of formaldehyde has also been assessed by other international 
bodies (EHC, 1989; Health Canada, 1999; CICAD, 2002; Afssa, 2004; IARC, 2006; BfR, 2006). 
Commission Regulation No 10/2011 on plastic materials and articles intended to come into contact 
with food
12 also set a specific migration limit of 15 mg/kg for  both formaldehyde and HMT. HMT (E 
239) can be used outside the EU as a preservative in other cheeses (ripened cheeses, including rind) if 
technologically justified and only within the functions and limit specified (JECFA, 2006). 
2.8.  Exposure assessment 
Food consumption data used for exposure assessment 
                                                       
12   Commission Regulation (EU) No 10/2011 of 14 January on plastic materials and articles intended to come into contact  
    with food. OJ L 12/1, p 1-89 Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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Since  2010,  the  EFSA  Comprehensive  European  Food  Consumption  Database  (Comprehensive 
Database) has been populated with data from national information on food consumption at a detailed 
level. Competent authorities in the European countries provide EFSA with data on the level of food 
consumption by the individual consumer from the most recent national dietary survey in their country 
(cf. Guidance of EFSA „Use of the EFSA Comprehensive European Food Consumption Database in 
Exposure Assessment‟ (EFSA, 2011a). 
The food consumption data gathered by EFSA were collected using different methodologies and thus 
direct country-to-country comparison should be made with caution. 
For calculation of chronic exposure, intake statistics have been calculated based on individual average 
consumption over the total survey period excluding surveys with only one day per subject. High level 
consumption was only calculated for those foods and population groups were the sample size was 
sufficiently  large  to  allow  calculation  of  the  95
th  percentile  (EFSA,  2011b).  The  Panel  estimated 
chronic  exposure  for  the  following  population  groups:  toddlers,  children,  adolescents  and  adults. 
Calculations were performed using individual body weights. 
Thus, for the present assessment, food consumption data were available from 26 different dietary 
surveys carried out in 17 different European countries as mentioned in Table 3:  
Table 3:   Population  groups  considered  for  the  exposure  estimates  of  HMT,  expressed  as 
formaldehyde. 
Population  Age range  Countries with food consumption surveys 
covering more than one day 
Toddlers  from 12 up to and including 
35 months of age 
 Bulgaria, Finland, Germany, Netherlands 
Children
13\  from 36 months up to and 
including 9 years of age  
Belgium,  Bulgaria,  Czech  Republic, 
Denmark,  Finland,  France,  Germany, 
Greece,  Italy,  Latvia,  Netherlands,  Spain, 
Sweden  
Adolescents  from 10 up to and including 
17 years of age  
Belgium, Cyprus, Czech Republic, Denmark, 
France,  Germany,  Italy,  Latvia,  Spain, 
Sweden 
Adults  from 18 up to and including 
64 years of age 
Belgium,  Czech  Republic,  Denmark, 
Finland, France, Germany, Hungary, Ireland, 
Italy,  Latvia,  Netherlands,  Spain,  Sweden, 
UK  
The elderly
13   from  65  years  of  age  and 
older 
Belgium,  Denmark,  Finland,  Fr ance, 
Germany, Hungary, Italy 
 
Consumption records were codified according to the FoodEx classification system (EFSA, 2011a). 
Nomenclature from FoodEx classification system has been linked to the Food Classification System as 
presented in the Annex II of Regulation (EC) No 1333/2008, part D, to perform exposure estimates. 
                                                       
13   The terms “children” and “the elderly” correspond respectively to “other children” and the merge of “elderly” and “very  
    elderly” in the Guidance of EFSA on the „Use of the EFSA Comprehensive European Food Consumption Database in  
    Exposure Assessment‟ (EFSA, 2011b). Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
 
EFSA Journal 2014;12(6):3696  14 
2.8.1.  Exposure to HMT (E 239) from its use as food additive 
Exposure to HMT (E 239) from its use as a food additive in Provolone cheese was calculated using the 
Maximum Permitted level (MPL) of 25 mg/kg residual amount, expressed as formaldehyde, combined 
with national consumption data for the five population groups (Table 3). 
Provolone cheese is not separately codified in the Food Classification System (FCS) of Annex II of 
Regulation (EC) No 1333/2008, part D. To avoid an overestimation of the exposure by assuming that 
the food group 1.7.2 Ripened cheese of the FCS consists of only Provolone cheese, the exposure 
assessment was performed using the food consumption data of the Comprehensive database codified 
according to FoodEx. In this classification system, Provolone cheese is codified as such. Examination 
of  this  database  showed  that  this  cheese  is  solely  codified  in  the  Italian  survey.  Based  on  these 
consumption data an exposure assessment was performed per population group. 
Mean  exposure  to  HMT  was  calculated  using  the  mean  consumption  of  Provolone  cheese  per 
population group for both the total population and the consumers only. The high level exposure was 
calculated per population group using the 95
th percentile (P95) of the total population and consumers 
only. These consumption levels were combined with the MPL of 25 mg/kg residual amount, expressed 
as formaldehyde. The high level of exposure was only calculated when the number of individuals per 
population group was at least 60 (EFSA, 2011b). 
Table 4 summarises the estimated exposure to HMT, expressed as formaldehyde, from its use as food 
additive in Provolone cheese in the five population groups living in Italy. The mean exposure to HMT, 
expressed as formaldehyde, for the total population was similar in all population groups (average 
0.3 µg/kg bw/day). For the consumers only, the mean intake of HMT, expressed as formaldehyde, 
from Provolone cheese was highest in the population group children: 20 µg/kg bw/day. The high level 
of exposure for consumers only could only be calculated for the adults and equalled 18 µg/kg bw/day 
(Table 4). 
In the absence of data at that level of detail from other EU countries, it was assumed that the whole 
food group 1.7.2 Ripened cheese of the FCS consists of only Provolone cheese, the exposure can be 
calculated  using  the  food  additives  intake  model  (FAIM),  available  on  the  EFSA  website 
(http://www.efsa.europa.eu/en/topics/topic/additives.htm).  Using  this  conservative  assumption  the 
highest exposure that could be calculated, using the P95 of consumers only combined with the MPL, 
equalled 87 µg/kg bw/day in children. Since Provolone cheese is probably only a niche product in 
many countries this figure is likely to be an overestimate. Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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Table 4:   Summary  of  anticipated  exposure  to  residual  amounts  of  HMT  (expressed  as  µg/kg 
bw/day of residual level of formaldehyde), from its use as food additive in Provolone cheese using the 
MPL in five population groups from survey in Italy: 
 
Toddlers 
(12-35 
months) 
Children 
(3-9 years) 
Adolescents 
(10-17 
years) 
Adults 
(18-64 
years) 
The elderly 
(>65 years) 
No subjects           
Total population 
Consumers only 
36 
2 
193 
5 
247 
9 
2313 
73 
518 
21 
Estimated exposure using MPL 
Total population 
  Mean  
  High level
14 
0.3 
- 
0.5 
- 
0.3 
- 
0.3 
- 
0.4 
- 
Consumers only           
  Mean  
  High level
14 
5.0 
- 
20 
- 
8.3 
- 
8.1 
18 
9.5 
- 
2.8.2.  Exposure from other sources                                
Formaldehyde is permitted in Food Contact Materials (FCM) with a specific migration limit of 15 
mg/kg (Regulation (EU) No 10/2011). Assuming the daily amount of consumed food which has been 
in contact with FCM being 1 kg, the additional exposure from FCM is 15 mg/day, which corresponds 
to 214 µg/kg bw/day for adults (70 kg), 283 µg/kg bw/day for adolescents (53 kg), 652 µg/kg bw/day 
for children (23 kg) and 1250 µg/kg bw/day for toddlers (12 kg). 
Furthermore, HMT is used as a urinary tract antibacterial-antiseptic drug as well as for long-term 
prophylaxis of urinary tract infections. 
2.9.   Uncertainty analysis 
Uncertainties  in  the  exposure  assessment  of  HMT  have  been  discussed  above.  According  to  the 
guidance provided in the EFSA opinion related to uncertainties in dietary exposure assessment (EFSA, 
2007), the following sources of uncertainties have been considered and summarised below: 
                                                       
14   95
th percentile could not be calculated because less  than 5% of the Italian population in the database were consumers or  
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Table 5:   Qualitative evaluation of influence of uncertainties 
Sources of uncertainties  Direction(a) 
Consumption data: different methodologies / representativeness / 
under reporting / misreporting / no portion size standard  +/- 
Use of data from food consumption survey of few days to estimate 
long-term (chronic) exposure  + 
Use of the MPL as the residual concentration of HMT (expressed 
as mg/kg of residual level of formaldehyde) present in provolone 
cheese. 
+ 
 
(a): + = uncertainty with potential to cause over-estimation of exposure; - = uncertainty with potential 
to cause underestimation of exposure. 
3.  Biological and toxicological data 
The present opinion summarises the major studies on HMT evaluated by the SCF (1977), JECFA 
(JECFA, 1962, 1965, 1972, 1974) and reviewed by TemaNord (2002). More recently, HMT has also 
been reviewed and evaluated by EPA (2006) and BAuA (2008), and these evaluations contain studies 
not included in the previous evaluations by SCF (1977), JECFA (1962, 1965, 1972 and 1974) and 
TemaNord  (2002).  An  additional  source  of  information  was  the  registration  dossier  provided  by 
industry for HMT under the REACH Regulation 1907/2006, published by the European Chemicals 
Agency (ECHA, 2011). The present document also reports the new literature data. 
Since  under  acid  conditions  or  in  the  presence  of  proteins,  HMT  is  converted  to  ammonia  and 
formaldehyde  (Hutschenreuter,  1956),  and  HMT  generated  free  formaldehyde  in  the  stomach 
(Malorny & Rietbrock, 1963), the SCF considered toxicological information on formaldehyde and its 
main  metabolite  formic  acid  was  relevant  to  the  assessment  of  HMT  (SCF,  1977).  The  BAuA 
evaluation (2008) stressed that formaldehyde formation from HMT is strongly dependent on acidic pH 
values. Therefore, formaldehyde generation would be relevant following oral ingestion as the pH of 
the stomach is acidic (BAuA, 2008). At the authorised levels of use, the levels of ammonium ion 
produced would not be relevant for risk assessment. 
In 2006, EFSA evaluated the safety of formaldehyde used as a preservative during the manufacture of 
food additives. The opinion did not re-evaluate the toxicology of formaldehyde per se but identified 
toxicological reference values for oral exposure (EFSA, 2006). The toxicity of formaldehyde has been 
extensively addressed by other international organizations (EHC, 1989; Health Canada, 1999; CICAD, 
2002; Afssa, 2004; IARC, 2006; BfR, 2006). 
3.1.  Absorption, distribution, metabolism and excretion 
3.1.1.  In vitro and animal studies 
Both JECFA (1962, 1965, 1972, and 1974) and BAuA (2008) described a series of toxicokinetics 
studies  on  HMT,  formaldehyde  and  formic  acid  both  in  vitro  and  in  animals  and  the  results  are 
summarised below. Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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3.1.1.1.  HMT 
It has been reported that under acid conditions, or in the presence of proteins, HMT is converted to 
ammonia  and  formaldehyde  (Hutschenreuter,  1956;  Restani  and  Galli,  1991),  and  that  HMT  also 
generated free formaldehyde in the stomach (Malorny & Rietbrock, 1963). 
Musher et al. (1974) as well as Strom et al. (1993) studied HMT (as methenamine) metabolism in vitro 
and examined the effect of the  pH in the urine on the conversion rate of HMT to formaldehyde 
(BAuA,  2008).  Both  groups  showed  that,  under  acidic  condition,  HMT  was  hydrolyzed  to 
formaldehyde at a rate mainly dependent on pH. Musher et al. (1974) reported that concentrations of 
formaldehyde  higher  than  25  µg/mL  could  be  achieved  in  urine  containing  more  than  0.6  mg 
HMT/mL at pH ≤ 5.7 or more than 1 mg/mL at pH ≤ 5.85. In another study, the half-life of HMT 
conversion to formaldehyde was shown to increase approximately 20 fold from 20 hours at pH 5.0 to 
about 400 hours at pH 6.5 (Strom et al., 1993). 
In mice orally administered radioactive HMT (as hexamine), 80% of the radioactivity was excreted in 
the  urine  within  3-4  hours,  mainly  unchanged  and  partially  as  free  formaldehyde.  Only  2%  was 
excreted via the lungs as CO2. After 22 hours, 4% of the radioactivity was still present in the body. 
HMT was also found in the liver and bones of the fetuses of pregnant mice (Schlede, 1966). 
3.1.1.2.  Formaldehyde and formic acid 
The EFSA evaluation (EFSA, 2006) summarised information on the toxicokinetics of formaldehyde in 
animal species taken from the BfR evaluation (BfR, 2006) reporting that, following oral ingestion in 
rats, formaldehyde in the blood was converted to formic acid within 90 seconds and half the ingested 
14C radio-labelled dose was eliminated as CO2 within 12 hours, and via the urine and faeces in rats 
(EFSA, 2006). The remaining radioactivity was found in several tissues, possibly due to metabolic 
incorporation into the single carbon pool and consequent inclusion into biological macromolecules 
(EFSA, 2006). It was also reported that, in different mammalian species, including humans, levels of 
formaldehyde in blood were similar to physiological blood-levels (~ 0.1 mM) indicating that systemic 
availability of formaldehyde was low (EFSA, 2006). Due to its high chemical reactivity and to its 
rapid metabolism in lining cells, local effects of formaldehyde appeared to play a more significant role 
compared to systemic effects (EFSA, 2006). 
EFSA,  2014,  evaluated  the  oral  internal  dose  of  formaldehyde  in  humans  from  endogenous 
production, food-derived from target animals exposed to formaldehyde-treated feed and formaldehyde 
generated  from  dietary  sources  of  methanol,  including  from  food  additives  such  as  aspartame. 
Endogenous turnover of formaldehyde was estimated to be approximately 0.61-0.91 mg/kg bw per 
minute and 878-1310 mg/kg bw per day assuming a half life of 1-1.5 min (EFSA, 2014). 
3.1.2.  Human studies 
3.1.2.1.  HMT 
The 2008 BAuA evaluation (BAuA, 2008) described a series of toxicokinetics studies on HMT (as 
methenamine) in human volunteers (BAuA, 2008) and the results are summarised below. 
After  oral  administration  of  a  single  1  g  dose  of  methenamine  hippurate  to  four  volunteers,  the 
maximum plasma concentration (70 – 100 μmol/L) was reached within 1 to 2 hours, and the mean 
elimination half-life was about 4 hours. The average distribution volume was close to the total body 
water in adults (about 0.6 L/kg). The renal clearance values (mean 71 mL/min) were lower compared 
to  the  plasma  clearance  value  (mean  93  mL/min).  In  cross-over  experiments  over  6  days,  after 
multiple dosing of tablets and granules of methenamine hippurate (1 g/12 hours), about 80% of the 
dose administered in each period was recovered in the urine within 12 hours (Allgen et al., 1979). The 
recovery of HMT in urine was slightly higher from tablets (total mean value = 83 ± 1.9%) than from 
granules (total mean value = 78 ± 1.8%).  Methenamine hippurate (1 g tablets as a single dose) was 
also administered to 8 healthy pregnant women during labour and for lactational transfer in 4 nursing Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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mothers. Data showed that in umbilical cord plasma HMT concentrations were initially low, but after 
4 hours were about at the same level as that in maternal plasma, indicating that HMT slowly passed 
the  placenta  without  accumulation  in  the  fetal  circulation.  However,  HMT  concentrations  in  the 
amniotic fluid were low and varied (between 4 and 63 µmol/L), and there was no correlation to the 
concentration in umbilical cord or maternal plasma. The authors noted that the study design meant 
umbilical cord samples were taken at different times post-dosing. The HMT concentrations in breast 
milk (range 48-52 µmol/L) were also found to be in the same range as in maternal plasma five hours 
after dosing. Therefore, the authors concluded that no accumulation of HMT occurred in milk, and 
could be safely given to pregnant and breastfeeding women. The amount of HMT uptake by the child 
during a respective meal was calculated to be far below the usual therapeutic doses (of 5-10 mg/kg 
bw) given to adults (Allgen et al., 1979). 
In  a  crossover  study  (Klinge  et  al.,  1982),  two  formulations  of  methenamine  hippurate  were 
administered to ten healthy volunteers (6 women and 4 men) as a single dose (1 g) on the first day and 
then  1  g  twice  a  day  for  8  days.  After  a  week  of  wash  out  period,  the  second  formulation  was 
administered for another 8 days. The serum maximum concentration of 35.2 mg/L after a single dose 
was achieved within 1 hour and the mean serum elimination half-life was reported to be 4.3 hours. The 
distribution volume was 0.56 L/kg, and no accumulation was reported. After a single dose, about 82% 
was recovered in the urine within 24 hours, and during each 12 hours dosing intervals, about 88% was 
recovered. In the urine, the average minimum concentration did not go below 150 mg/L (Klinge et al., 
1982). 
In another cross-over study, Gollamudi et al. (1981) measured the urinary excretion of both HMT and 
formaldehyde  for  48  hours  after  the  oral  administration  of  10  different  HMT  formulations  (as 
methenamine or its mandelate or hippurate) containing between 0.439-0.500 g of HMT to ten male 
human volunteers.  It was reported that there were no significant differences among HMT and its 
various salts on the total excretion of free formaldehyde (ranging from 5.5 to 8.7% of the oral dose) in 
the  urine  at  48  hours.  However,  differences  were  noted  among  the  different  formulations  on 
cumulative excretion of total HMT (varying from 16 to 83% of the oral dose) (Gollamudi et al., 1981). 
The BAuA evaluation (BAuA, 2008) reported that there was evidence that approximately 10-20% of 
an oral dose of HMT was converted to formaldehyde and ammonia in the stomach (Gleckman et al. 
(1979). In another study, methenamine mandelate was administered to 13 healthy men as oral doses of 
1 g, 4 times/day. The average content of free  formaldehyde collected in the urine was about 6% 
(varying from 3.2 to 16.6%) (Gandelman et al., 1967). 
Greenfield et al. (1969) examined the urine excretion of formaldehyde in 8 healthy male volunteers 
receiving orally, on separate days, 390 g of  HMT, 1 g-dose of methenamine mandelate (480 mg 
HMT, 520 mg mandelic acid), methenamine sulfosalicylate (390 mg HMT, 610 mg sulfosalicylate), 
methenamine hippurate (470 mg HMT, 530 mg hippuric acid) in a 8-hours crossover study. In a 
second 24-hours crossover study, 4 g methenamine mandelate or methenamine sulfosalicylate, and 2 g 
of methenamine hippurate were given orally, on separated days, to 4 volunteers. Data showed that 
peaks levels of free formaldehyde occurred at 2 hours in the 8-hours study, and at 4-6 hours in the 24-
hours study. According to the authors, this delay in formaldehyde release (especially marked in the 24-
hours study with methenamine mandelate) was mainly due to the different types of formulations which 
could delay the absorption of the drug until the lower small intestine.  In the same study, it was also 
reported a direct influence of pH on formaldehyde release from HMT (0.5 mg/mL). At pH of 5.4-5.7, 
108 µg/mL of formaldehyde was recovered. However, substantial production of formaldehyde (37 
µg/mL) occurred also at slightly alkaline pH (8.1-8.2) (Greenfield et al., 1969). 
3.1.2.2.  Formaldehyde and formic acid 
More recently, the BAuA evaluation (2008) reported that, following oral ingestion, formaldehyde can 
be absorbed and converted to formic acid within 90 seconds. The elimination half-life of formic acid 
was reported to be 90 minutes. Formic acid can be excreted through the kidney as its sodium salt or is Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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further oxidised to CO2 and water (Pandey et al., 2000; BAuA, 2008). The rate of conversion of formic 
acid to CO2 and water was reported to be approximately 50% more rapid in rodents than in primates 
(Pandey et al., 2000; BAuA, 2008). The relative slow metabolism of formic acid in humans can lead to 
metabolic acidosis, due to accumulation of formic acid (Pandey et al., 2000; BAuA, 2008). The same 
authors reported two other studies in human. In the first study in which 11 volunteers were given 
formate  intravenously  (dose  not  specified),  the  average  elimination  half-life  of  formate  was  55 
minutes.  In  a  second  study  in  which  11  volunteers  were  given  formate  orally,  the  half  -life  was 
reported to be 45 minutes (dose of 3 g of formate), and 46 minutes (dose of 4.4 g for formate) (Pandey 
et al., 2000; BAuA, 2008). 
3.1.3.  Summary on the ADME of HMT and formaldehyde 
In summary, under acidic conditions, HMT was converted to formaldehyde, which in turn would be 
converted  into  formic  acid.    Overall,  both  in  animal  and  human  studies,  formaldehyde  is  rapidly 
absorbed and converted to formic acid. The rate of oxidation of formaldehyde to formic acid was 
comparable in all animal species, with a half-life of only 1 minute. The elimination half-life of formic 
acid is reported to vary from 55 minutes in animals to 90 minutes in humans and can be excreted via 
the kidneys or further oxidised to CO2 and water (JECFA, 1962, 1965, 1972, 1974; BAuA, 2008).  In 
humans, about 88% of the administered oral dose of 1 g HMT was absorbed within 12 hours and 
excreted mostly unchanged (about 82% of recovery) in the urine in 24 hours. The maximum serum 
concentration (35.2 mg/L) after a single dose was achieved within 1 hour and the mean elimination 
half-life in blood was reported to be 4.3 hours. Approximately 10-20% of an oral dose of HMT is 
converted  to  formaldehyde.  HMT  can  pass  the  placenta  and  is  detectable  in  breast  milk  of 
breastfeeding women; however, no accumulation was reported. Formaldehyde formation from HMT 
was dependent on pH , formaldehyde generation prior to absorption would be relevant following oral 
ingestion as the pH of the stomach is acidic and has been estimated as 10-20% of the dose. Further 
down the gastrointestinal tract, the pH is neutral with nearly no generation of formaldehyde. HMT can 
also be converted into formaldehyde in urine and the rate of conversion was pH dependent (BAuA, 
2008). 
3.2.  Toxicological data 
There are studies in the literature on HMT toxicity via other routes of administration (e.g. inhalation, 
dermal, subcutaneous). As these routes of exposure were not directly relevant to the toxicity of HMT 
from food additives, further details on these studies were not considered in this opinion. 
3.2.1.  Acute oral toxicity 
The JECFA (1962, 1965, 1972, 1974), the EPA (2006) and the BAuA (2008) evaluations provided 
summary  information  on  the  acute  oral  toxicity  of  HMT  and  formic  acid  and  its  salts,  and  the 
summary is presented below (JECFA, 1962, 1965, 1972, 1974; EPA, 2006; BAuA, 2008). A few more 
studies  were  also  reported  in  a  dossier  submitted  to  ECHA  (ECHA,  July,  2011.  Online  access: 
http://apps.echa.europa.eu/registered/registered-sub.aspx#search). 
In rats LD50 values of 10 g/kg bw or greater have been reported whilst values in mice were lower at 
around 2 g/kg bw. 
Two case report studies have been found in the literature. Tanaka and Kitajima (1976) reported a case 
study in which a man suffering from renal disturbance, died of post-operative bleeding accompanied 
by uremia, apparently related to treatment with HMT. Severe interstitial nephritis (e.g. intense cell 
infiltration, absence of glomerular involvement and marked softening and enlargement) of the kidney) 
was  reported  (Tanaka  and  Kitajima,  1976).  Another  more  recent  case  report  described  a 
photosensitivity reaction to methenamine hippurate in a 70-year-old woman after taking methenamine 
hippurate for several years to prevent urinary tract infections. An erythematous and blistering rash on 
the sun-exposed areas of her face, trunk and upper limbs was reported (Selvaag and Thune, 1994). Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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3.2.2.  Short-term and subchronic toxicity 
The  BAuA  evaluation  (2008)  describes  a  few  short-term/subchronic  studies  on  HMT,  which  are 
summarised below. 
Male and female rats (cPah strain, 5/sex) were treated by gavage with 1280 and 1780 mg HMT /kg 
bw/day  respectively  (purity  unspecified)  for  90  days.  Haematology  and  clinical  biochemistry 
parameters  were  not  measured.  There  was  no  HMT-induced  mortality  and  no  differences  from 
controls in behaviour, body weight gain and food consumption in rats of both sexes treated with HMT. 
The only clinical sign observed in animals given HMT was a citrus-yellow discolouration of the fur. 
No  differences  in  macroscopic  lesions  in  the  main  organs  of  treated  and  controls  animals  were 
observed.  However,  no  data  on  HMT-induced  histopathological  findings  were  available  (Brendel, 
1964). The yellow discolouration of fur observed in animals was attributed to a reaction between 
formaldehyde in the urine and kynurenine in the rat hair (Restani and Galli, 1991). 
10-week old Wistar rats (10/sex) received a high concentration of 5.0% HMT (equivalent to 5000 
mg/kg bw/day, based on body weights of 250 g in males and 200 g in females and an average water 
consumption of 10% of the body weight) daily in the drinking water for two weeks with a subsequent 
102-week  treatment-free  period.  About  half  of  the  rats  of  both  sexes  died  within  one  week  after 
treatment. Specific causes of death were not reported. Surviving rats recovered rapidly and showed no 
toxic effects. The only treatment related clinical observation was a citrus-yellow discolouration of the 
hair  coat  which  was  considered  of  no  toxicological  relevance.  Data  on  haematology  and  clinical 
biochemistry were not available. Growth, necropsy and histopathology of the treated animals showed 
no specific changes due to HMT (Della Porta et al., 1968). 
The EPA evaluation (EPA, 2006) reported two other studies in mice and rabbits. Mice fed HMT at 
doses up to 5 g/kg bw for 10 days showed no toxic effects (CIR, 1992). A study in rabbits fed HMT 
intermittently at a dose of 525 mg/kg bw for 15 weeks showed that HMT induced decreased body 
weight gain or weight loss (RTECS, 2005 as referenced in EPA 2006). 
Short-term toxicity of spinacine. 
Short term toxicological studies with spinacine, the most abundant end-product of formaldehyde in 
cheese (derived from the N-terminal histidine residue in gamma 2-casein) showed a NOAEL of 300 
mg/kg  bw/day.  From  these  results,  the  authors  suggested  a  Tolerance  Level  (TL)  of  1800  mg 
spinacine/kg  cheese.  The  authors  concluded  that  there  was  no  appreciable  health  risk  from 
consumption of cheese made using formaldehyde (Grana Padano) or HMT (Provolone) (Restani and 
Restelli, 1992). 
In conclusion, there is limited information available on the subchronic toxicity of HMT.  None of the 
studies provided data on haematology and clinical chemistry; data on histopathology were limited. 
However,  body  weight  gain,  food  consumption,  survival,  organ  weights,  gross  pathology  and 
histopathology were generally unaffected following exposure to HMT. The only  treatment related 
clinical observation in studies with rats was a yellow staining of the perineal hair in some cases and 
decreased body weight gain or weight loss in a 15 weeks study in rabbits. 
3.2.3.  Genotoxicity 
Previous evaluations 
The JECFA evaluation (JECFA, 1974) reported that both HMT (Auerbach, 1951) and formaldehyde 
(Rapoport,  1946  as  reported  in  JECFA  1974)  were  shown  to  be  mutagenic  in  Drosophila 
melanogaster. 
In 1991 it was reported that HMT did not act as a clastogen on Vicia faba roots and V79 cells but 
increased  the  frequency  of  sister-chromatid  exchanges  in  V79  cells  in  the  absence  of  metabolic Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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activation (Girmanova et al., 1991). HMT was found positive in Ames test in S. typhimurium strains 
TA 98 and TA 100 without metabolic activation systems and to be DNA-damaging in the rec assay on 
Bacillus subtilis spores strain H17 and M45 in absence of metabolic activation. High doses of HMT 
were reported to induce chromosomal aberrations both in mouse lymphocyte cultures and in human 
HeLa cell line. Moreover, morphological transformation was induced in baby hamster kidney cells. 
Mutagenic effects were not observed in a dominant lethal test in C3H mice (Loeper and Berzins, 
1995). 
The EPA evaluation (EPA, 2006) reported a study by Orstavik and Honglso (1985) showing that 
extracts of a sealer compound (AH26), which contains also 25% of HMT, were mutagenic in strains 
TA 100 in a dose-dependent manner, with or without S9 metabolic activation. However, HMT was 
negative for mutagenicity when tested individually (Orstavik and Honglso, 1985). 
The Panel noted that some of the test systems considered in previous evaluations, i.e. cytogenetic tests 
in plant cell, the rec assay in bacteria, and cell transformation in BHK cells, have received insufficient 
validation or are considerd unreliable for genotoxicity assessment. 
More recently, the BAuA reported a series of in vitro and in vivo studies with HMT (BauA, 2008), 
whose results are summarised below: 
In vitro assays with bacteria 
In bacterial gene mutation assays with HMT, weak positive effects with and without S-9 mix were 
reported for S. typhimurium strains TA 97, TA 98 and TA 100 (approx. 2-fold increases compared to 
control values) only at high concentrations, viz. from 10,000 μg/plate (Zeiger et al., 1992). In another 
study, increased numbers of mutant colonies (compared to the control value) were observed only at 
concentrations higher than 5000 μg/plate in S. typhimurium strains TA 98 and TA 100 (Shimizu et al., 
1985), while for strains TA 1535, TA 1537, TA 1538 and WP2uvrA up to 10 000 μg/plate negative 
results were observed with and without S-9 mix (BAuA, 2008). In a screening of rubber chemicals 
HTM, tested up to 5000 μg/plate, was negative in S. typhimurium strains TA 98 and TA 100 with and 
without metabolic activation (Crebelli et al., 1984). 
In vitro assays with mammalian cells 
In addition to the study by Girmanova et al (1991) mentioned by TemaNord, BauA quoted a poorly 
documented chromosomal aberration assay with HeLa cells in which negative results were found up to 
concentrations  of  1  mmol/L;  higher  concentrations  were  found  to  induce  strong  cytotoxic  effects 
(Baldermann et al., 1967). Dooley et al. (1985) reported a negative L5178Y TK
+/- mouse lymphoma 
assay with HMT under addition of formaldehyde dehydrogenase and NAD+ to the test system (limited 
information, abstract only). The Panel noted the limitations in study protocol and/or reporting of the in 
vitro studies in mammalian cells. 
Takahashi and Ono (1993), as reported to ECHA
15 in which negative effects of HMT on strains TA 98 
and TA 100 were observed, with or without metabolic activation. Another study in which HMT was 
tested  in  a  GreenScreen®  assay  in  S.  cerevisiae  at  different  concentrations  up  to  cytotoxic 
concentrations (highest dose: 300 µg/mL) in the absence of mammalian metabolic activation was also 
reported.  HMT  was  shown  to  be  genotoxic  in  the  GreenScreen  Assay  at  a  lowest  effective 
concentration of 150 µg/mL (Cahill et al., 2004). 
In vivo assays with mammals 
                                                       
15 (ECHA, methenamine, 2014 http://apps.echa.europa.eu/registered/data/dossiers/DISS-9d86c041-f4b7-44cd-e044- 
   00144f67d249/DISS-9d86c041-f4b7-44cd-e044-00144f67d249_DISS-9d86c041-f4b7-44cd-e044-00144f67d249.html)  Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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HMT was found to be negative in a chromosomal aberration test in mouse bone marrow with acute or 
repeated oral administration (Vujosevic et al., 1986). In the acute experiment HMT was given as a 
single oral dose at 618 mg/kg (corresponding to 1/3 of LD50-value) and two lower doses at 6, 12 and 
24 hours before sacrifice; in the repeat dose experiment, HTM was given in 5 daily administrations 
with sacrifice 6 hours after last dosing. No information about clinical symptoms or cytotoxic effects 
was reported by the authors. However, from the toxicokinetic data available BAuA concluded that the 
target organ was exposed to HMT (BAuA, 2008). 
Negative results were shown in a dominant lethal assay in mice after single intraperitoneal doses up to 
10 g HMT /kg bw. A second assay, in which oral doses of 25 g/kg (maximum tolerated dose) were 
administered, was considered not valid, due to higher frequencies of live implants in treated animals 
than in control animals (Baldermann et al., 1967). No positive controls were included (BAuA, 2008). 
With regards to the genotoxicity, HMT was weakly positive in bacterial gene mutation assays and in 
an indicator tests in yeast  and at high doses in tests for chromosomal aberrations and sister chromatid 
exchanges in  mammalian cells in vitro (BAuA,  2008). In vivo, negative results were  obtained in 
chromosomal aberration tests in mouse bone marrow by the oral route and in the dominant lethal test 
in mice by i.p. administration.  Based on these findings, the Panel concluded that the weak genotoxic 
potential elicited by HMT in vitro is not expressed in two limited in vivo assays. 
3.2.3.1.  Genotoxicity of formaldehyde. 
Different safety evaluations reported on the genotoxic effects of formaldehyde in different in vitro 
assays such as structural chromosomal aberrations, sister-chromatid exchanges, gene mutations, DNA 
strand breaks, DNA protein crosslinks, and DNA repair deficiencies in both bacterial and mammalian 
cells (EHC, 1989; CICAD, 2002; IARC, 2006; BfR, 2006), as cited in the  EFSA evaluation (EFSA, 
2006). The EFSA evaluation (EFSA, 2006) also reported that most available in vivo genotoxicity 
assays on formaldehyde are based on “local and/or systemic genotoxicity” animal models following 
exposure by inhalation. The majority of these in vivo genotoxicity studies indicated that any genotoxic 
potential  of  formaldehyde  was  limited  to  the  site  of  contact  and  did  not  occur  systemically  in 
experimental animals (BfR, 2006). The site of contact seems to be the preferred target of genotoxicity 
also after oral exposure: in a study in rats treated orally with formaldehyde (200 mg/kg bw), induction 
of micronuclei and nuclear anomalies in stomach, duodenum, ileum and colon compared to controls 
were  observed  (Migliore  et  al.,  1989;  BAuA,  2008).  These  effects  were  more  pronounced  in  the 
stomach, decreasing progressively at other sites of the gastrointestinal tract as the distance from the 
stomach increased (BAuA, 2008). 
3.2.4.  Chronic toxicity and carcinogenicity 
The JECFA evaluation (JECFA, 1972) reported a long-term/carcinogenic study in which NMRI/Han 
albino mice (30/sex/group) were fed 0% or 1% HMT or 0.15% formaldehyde for 2 years. Benign and 
malignant tumours were reported in 43 animals: 20 in the HMT group, 12 in the formaldehyde group 
and 11 in the control group. Except for 1 control male and 2 males in the HMT group, all tumours 
occurred  in  females.  29  out  of  36  malignant  tumours  were  subcutaneous  carcinomas  and 
adenocarcinomas (Kewitz and Welsch, 1966 as reported in JECFA, 1972). The same author conducted 
a further study in groups of 50 female mice fed HMT at levels of 0%, 0.1%, 0.5% and 1% for 31 
weeks. No differences in tumour incidence between the groups were observed (Kewitz, 1966). No 
further information is provided. In vitro formation of carcinogenic nitrosamine has been reported as a 
result of the interaction of nitrite with HMT at pH between 1-3 (JECFA, 1974). 
In other studies in mice, HMT was tested in three different strains: CTM, outbred; C3Hf/Dp, inbred; 
and SWR/Dp, inbred. 96 males and 102 females CTM mice (10 weeks old) received 0, 0.5, 1, or 5% 
HMT in drinking water for 30 or 60 weeks. In the C3Hf/Dp mice (5 weeks old) 49 males and 44 
females received 1% HMT in the drinking water over a period of 60 weeks (calculated daily intake of 
2.5 g HMT/kg bw/day in either sex). In the SWR/Dp mice (7 weeks old), 29 males and 27 females 
mice received 1.0% HMT in drinking water for 60 weeks (calculated daily intake of 2.5 g HMT/kg Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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bw/day in either sex). Mice were observed up to 100 weeks of age. No significant differences were 
observed in body weight gain between control and HMT-treated SWR and C3Hf strain groups. Water 
intake was similar in both control and HMT-treated groups. No data on haematology and clinical 
biochemistry were reported. Treatment of CTM mice with 5% HMT (12.5 g HMT/kg bw/day) for 30 
weeks showed a significant reduction in survival rates and slight reduction of growth in the surviving 
animals.  Slight  retardation  of  growth  was  also  seen  in  SWR  mice  treated  with  1%  HMT  (2.5  g 
HMT/kg bw/day). The effect on growth in SWR mice was very small, and not statistically significant, 
and no findings were noted at necropsy and microscopy. In addition, there were no HMT-related gross 
and microscopic findings in mice of all tested strains (Della Porta et al., 1968). Therefore, based on 
these results the BAuA evaluation (2008) established a NOAEL for mice of 2.5 g HMT/kg bw/day 
HMT in either sex (BAuA, 2008). The EPA evaluation (2006), however, reported for the same study a 
NOAEL of 12.5 g HMT/kg bw/day, the highest dose tested, and no LOAEL was established. No 
carcinogenic activity was reported (EPA, 2006). 
TemaNord (2002) described chronic toxicity studies in dogs and rats receiving oral HMT in a dosage 
of 50-200 mg HMT/kg daily and 0.8-6.4 g HMT /kg daily, respectively. Gastric and bladder irritation 
occurred with some hemorrhagic sites and ulceration (TemaNord, 2002). 
The BAuA evaluation (2008) reported different long-term studies in animals following oral exposure. 
These studies are only shortly reported and have not been evaluated in details in the original document 
by the Panel because they are not considered an adequate basis for establishing health based guidance 
values. 
BD (cPah) rats (15/sex) were treated with an average calculated dose of 1130 mg HMT/kg bw/day for 
males and 1570 mg HMT/kg bw/day for females. Haematology and clinical biochemistry parameters 
were not measured. Except for citrus-yellow fur discolourations, no difference in macroscopic and 
microscopic findings in organs or in body weight gain between treated and control groups of both 
sexes were observed. No tumours were reported (Brendel, 1964). Based on the results of this study, 
the BAuA evaluation (2008) reported a NOAEL of approximately 1130 mg HMT /kg bw/day in males 
and 1570 mg/kg bw/day in female BD (cPah) rats, the only doses tested(BAuA, 2008). 
Outbred Wistar rats (10 weeks old, 48/sex) received either 0 or 1.0% HMT in the drinking water for 
104  weeks  (calculated  intake  1.5-2  g  HMT/kg  bw/day  in  males  and  2-2.5  g  HMT/kg  bw/day  in 
females). After the end of treatment period rats were observed for a subsequent treatment-free period 
of up to 3 years of age. Body weights showed no significant differences between controls and HMT 
treated groups. Water intake was also comparable in both control and HMT treated test groups. There 
were  no  data  on  haematology  and  clinical  biochemistry.  Survival  was  84%  in  HMT-treated  and 
untreated animals at the end of the experiment. In all HMT-treated rats a yellow colouration of the 
coat was observed. No pathological lesions related to HMT treatment were observed in rats that died 
during the study or sacrificed at the end of the test (Della Porta et al., 1968). Based on these results, 
the BAuA evaluation (2008) reported a NOAEL of 1.0% (calculated intake 1.5-2 g HMT/kg bw/day in 
males and 2-2.5 g/kg bw/day in females), the only doses tested. 
 In another experiment, outbred Wistar rats (10 weeks old, 12/sex) received a high concentration of 
5.0% HMT (equivalent to 5 g HMT/kg bw/day, based on body weights of 250 g in males and 200 g in 
females and an average water consumption of 10% of the body weight) daily in the drinking water for 
two weeks with a subsequent 102-week treatment-free period. 50% mortality was observed after 2 
weeks,  but  no  other  treatment-related  histopathological  changes  were  recorded  (BAuA,  2008). 
Therefore, the BAuA evaluation (2008) reported a LOAEL of 5 g/kg bw/day).  The EPA evaluation 
(2006) reported for the same study a LOAEL of 7.25 g/kg bw/day (EPA, 2006). The Panel noted that 
these reported intakes appeared high based on the available information on normal water consumption 
in rats. 
Wistar rats (two months old, 16/sex/group) were given in the diet either 0 or 0.16% HMT (equivalent 
to 100 mg/kg bw/day) from weaning to natural death. Data on haematology and clinical chemistry Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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were not available. No significant differences between controls and HMT-treated animals were shown 
with regards to general health and behaviour. Only a yellow staining of the perianal hair was observed 
in  one  male  and  three  female  rats  treated  with  HMT.  No  significant  differences  were  observed 
between  HMT  treated  animals  and  control  with  respect  to  body  weight,  muscular  activity,  organ 
weights,  histopathological  findings,  life-span  and  causes  of  death  (Natvig  et  al.,  1971).    In  an 
additional palatability experiment, albino rats (10-12 week old) were allowed to choose between food 
containing HMT and the same food without HMT for a 28-day period (the two types of food were 
consumed in a similar amount). After a 120-day period during which they were fed only the HMT 
enriched diet, the animals were again allowed to choose between the two diets in a second 28-day trial. 
The addition of HMT had no effect on palatability of the diet (Natvig et al., 1971). Therefore, in this 
chronic oral toxicity study in Wistar rats the BAuA evaluation (2008) reported a NOAEL of 100 mg 
HMT/kg bw/day for both sexes (BAuA, 2008). 
Sprague-Dawley rats (8-10 weeks old, 15/sex/group) were given 0.1% HMT in drinking water. Each 
group received a total dose of 5 g HMT equivalent to 80 mg HMT/kg bw/day in males and 100 mg 
HMT/kg bw/day in females, based on a body weight of 250 g in males and 200 g in females), either 
with or without 0.2% sodium nitrite (total dose of 10 g nitrite per rat) on 5 days/week for a period of 
50 weeks. There were no data on haematology and clinical biochemistry. No significant differences in 
the survival rate were reported.  No tumours findings were reported either in animals fed HMT alone 
or in combination with nitrite (Lijinsky and Taylor, 1977). Based on these data, the BAuA evaluation 
(2008) reported a NOAEL for HMT of 80 mg HMT/kg bw/day for males and 100 mg HMT/kg bw/day 
for females (BAuA, 2008). 
In a comparative study in cats, one group of two male and three female cats received a diet containing 
1250 mg HMT/kg diet. Each cat received a total dose of 180 g HMT for 742 days. The mean dose per 
cat for a period of two years was estimated to be approximately 61 mg HMT/kg bw/day (assuming a 
mean body weight of 4 kg for both sexes). Another group of cats, one male and three females, were 
fed a diet containing 374 mg formaldehyde/kg diet for 106 weeks (equivalent to approximately 20.88 
mg formaldehyde/kg bw/day for both sexes, based on feed consumption resulting in a total dose of 62 
g/cat). A third group of three male and female cats were the control. One female in the formaldehyde 
group died after seven months of pleurisy and a female in the HMT group died after twenty-three 
months of a pyrogen infection in the nasal cavity and paranasal sinuses. No treatment-related effects 
were found concerning food consumption, body weight gain, or behaviour in animals treated with 
HMT.  There  were  no  data  on  haematology,  biochemistry  and  histopathology  (Kewitz,  1966, 
unpublished report). Based on the results reported, the BAuA evaluation (2008) reported a NOAEL of 
61 mg HMT/kg bw/day for male and female cats (BAuA, 2008), the only dose tested. 
In summary, available information on the chronic toxicity of HMT was limited. None of the studies 
provided data on haematology and clinical chemistry. Body weight gain, food consumption, organ 
weights, gross pathology and histopathology were unaffected following exposure to HMT. However, 
survival rates and growth were significantly decreased in a study in CTM mice treated with 12.5 g 
HMT/kg bw/day for 30 weeks. The only treatment related clinical observation in studies with rats was 
occasional yellow staining of the perineal hair. Overall, HMT was not carcinogenic in experimental 
animals treated at doses up to 2.5 g HMT/kg bw/day (Brendel, 1964; Natvig et al., 1971; Della Porta, 
1968; Lijinsky and Taylor, 1977). For all the studies, the NOAELs for HMT corresponded to the 
highest dose tested.  The BAuA (2008) evaluation reported that the existing long-term/carcinogenicity 
studies on HMT were not in line with the current guidelines on carcinogenicity and/or combined 
chronic toxicity/carcinogenicity. However, the data submitted were considered useful in assessing the 
carcinogenic potential of HMT. In addition, considering the negative results from in vivo genotoxicity 
testing, BAuA concluded that HMT was not considered as carcinogenic for experimental animals 
(BAuA,  2008).  The  BAuA  evaluation  (2008)  also  reported  that  one  valid  cancer  study  with 
formaldehyde administered via drinking water to rats did not show an increased tumour incidence in 
any organ (Til et al., 1989). The Panel concluded that the formation of formaldehyde from HMT 
should not be of concern with regards to carcinogenicity. Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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The relevant long-term studies using oral administration of formaldehyde have been discussed in the 
EFSA evaluation in 2006 (EFSA, 2006). 
The EFSA 2006 evaluation reported that the evaluation of these studies indicated that currently, there 
is no definitive evidence to indicate that formaldehyde is carcinogenic when administered orally to 
laboratory animals. Other evaluations concluded more recently that the overall weight of evidence on 
systemic carcinogenicity of formaldehyde in animals is insufficient to indicate that formaldehyde has 
the potential to induce tumours  of the haemopoietic system  or the gastrointestinal tract  after oral 
intake. Consistent with the cytotoxic effects seen at sites of contact for the inhalation route, repeated 
oral  administration  of  formaldehyde  induces  erosion/ulceration  effects  in  the  forestomach  and 
glandular stomach and hyperplasia of the limiting ridge and glandular stomach. Such a mechanism 
may also include a threshold response.  Therefore, the EFSA evaluation (2006) concluded that: „The 
Panel examined recent and previous evaluations of formaldehyde and concluded that there was no 
evidence indicating that formaldehyde is carcinogenic by the oral route‟ (EFSA, 2006). 
3.2.5.  Reproductive and developmental toxicity 
The 1972 JECFA evaluation (JECFA, 1972) reported several reproductive and developmental studies 
in different animal species and these data are described below. 
In a 5-generation study lasting three and half years, a total of 80, 80 and 245 rats were given 0, 5 and 
50 mg HMT/kg day in the drinking-water. No treatment-related changes were found (Malorny, 1966). 
In an unpublished study submitted to JECFA (1974) by Berglund (1966) rats (10/sex) were fed doses 
equivalent
16 to 0, 20, 40 and 80 mg HMT/kg bw/day for 2 years. There were no effects at any dose on 
growth, 2-year survival, reproduction and viability of offspring. No specific pathological changes were 
observed at any dose level (Berglund, 1966). 
The  JECFA  described  studies  in  dogs  with  small  numbers  of  animals  dosed  with  HMT  and 
formaldehyde.  The  limited  reports  of  these  studies  reported  no  consistent  effect  of  HMT  or 
formaldehyde on the parameters measured (Kewitz, 1966, Tierfarm, 1969). 
The BAuA evaluation (BAuA, 2008) described other studies on reproductive and developmental 
toxicity of HMT in animals and in human. The results of these studies are summarised below. 
Reproduction was investigated in a lifetime feeding study on Wistar rats fed with a standard diet of 
0.16% HMT (corresponding to about 100 mg HMT/kg bw/day) (Natvig et al., 1971).  After three 
months of treatment, 16 males and 16 females of the treated group were mated.  16 males and 16 
females of the F1 generation were fed with the same diet as their parents from weaning. For the F1 
generation, no effects on average litter size were   noted, and no significant differences from the 
controls were found on muscular activity, general health, mean body weights at 7, 15, and 18 weeks of 
age and for relative organ weights (liver, kidney, adrenals, gonads) at 18 weeks of age (Natvig et al., 
1971). However, BAuA reported that no other parameters were evaluated and data available were 
limited (BAuA, 2008). 
Della Porta et al., (1970) conducted a further study on transplacental toxicity and carcinogenesis in 
two independent experiments for one and  for three successive generations in Wistar rats exposed to 
HMT via drinking water. In the first experiment 12 females and 6 males were given 1% HMT in 
drinking water (daily intake of approximately 1.5 -2 g HMT/kg bw/day for males and of 2 -2.5 g 
HMT/kg bw/day for females) during two weeks prior to mating through gestation and lactation. A 
similar untreated group of 12 females and 6 males served as controls. Within 25 -30 days after mating 
11 treated females and 11 controls became pregnant and delivered 110 and  118 pups, respectively. 
After delivery pups of both groups were reduced to 8 offspring per litter (treated group 47 males/38 
females, control group 37 males/46 females). After weaning, offspring (24/sex) were continued on 1% 
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HMT in drinking water up to the 20
th week of age. In treated males up to postnatal week 9 and in 
treated females up to postnatal week 13, the body weights were significantly lower than those of 
controls. However, at the beginning of the postweaning, the initial body weights of the offspring of 
treated females were already lower than those of the offspring of the controls, indicating that growth 
deficits were already present. No differences in body weights were recorded at the end of the 20 
weeks. No differences were noted between treated and control groups on organ weight and gross or 
microscopic findings at the end of the treatment (Della Porta, 1970). Based on the temporary weight 
loss, the EPA evaluation (2006) established a NOAEL of 1% HMT (corresponding to 1 500-2 000 mg 
HMT/kg bw/day for males and of 2 000-2 500 mg HMT/kg bw/day for females). The weight loss 
could be attributed to the decreased palatability of the drinking water (EPA, 2006). 
 In a second experiment (Della Porta et al., 1970) rats were given 1% HMT in drinking water for three 
successive generations, up to the age of 40 weeks in the F1 and F2 groups and of 20 weeks for the F3 
group. Afterwards, all groups were kept under observation up to week 130 of their lifetime. The F0 
generation group consisted of one male and two females that were given 1% HMT in drinking water 
during four weeks before mating. The treatment of the females continued until two litters of ten pups 
each had been weaned. The descendant F1 groups consisted of 13 males and 7 females. The females 
were mated to 3 males of their group. One dam died during delivery while the remaining 6 dams gave 
birth to a total of 36 pups from which 10 died during lactation. The resulting F2 group consisted of 15 
males and of 11 females. These females were mated to 4 males of their group and delivered a total of 
99 pups from which only 12 males and 12 females were further raised to form the F3 group. An 
additional group of 5 females was given 2% HMT from mating through lactation. They delivered a 
total of 49 pups from which 16 animals per sex were continued on 2% HMT for 50 weeks. A group of 
48 males and 48 females were the untreated control. All groups were observed for over two years of 
age. No differences on survival rates and on body weights of all offspring generations were reported. 
No evidence of carcinogenicity was found (Della Porta, 1970). No other parameters on reproductive 
endpoints  have  been  recorded  since  this  study  had  been  primarily  directed  to  elucidate  potential 
carcinogenicity (BAuA, 2008). 
In another  study, a group of 9 females Alpk:AP (Wistar-derived rats)  were  given  HMT  daily by 
gavage at dose of 1000 mg HMT/kg bw during gestation day 7 to 17 (Wickramaratne, 1987). A 
decrease in body weight gain was noted in treated animals. 5 pregnant females of the treated group 
showed no difference in mean litter size, survival of pups and pup postnatal weight gain. However, the 
BAuA evaluation (2008) reported that the number of dams for which offspring could be evaluated was 
limited  and  no  rationale  was  provided  to  explain the  reason  why  only  5 out  of  9 sperm-positive 
females produced litters (BAuA, 2008). 
HMT was given to 51 female beagle dogs at dietary concentration of 600 or 1250 mg HMT/kg diet 
(equivalent to doses of 15 or 31 mg HMT/kg bw/day, assuming an average body weight of 12 kg) 
from days 4 to 56 after mating (Hurni and Ohder, 1973). 9, 8, and 8 females provided litters from the 
control,  15  or  31  mg  HMT/kg  bw/day  groups,  respectively.  Further  groups  were  treated  with 
formaldehyde (125 and 375 mg formaldehyde/kg diet). Pregnancy rates, mean length of gestation, 
mean litter size or body weight gains of the mothers were not affected by treatment. The mean litter 
size was within the normal range for all groups (controls: 6.7; formaldehyde, 125 mg formaldehyde/kg 
diet: 5.4; formaldehyde, 375 mg formaldehyde/kg diet: 7.1;  HMT, 600 mg HMT/kg diet: 6.3; HMT, 
1250 mg HMT/kg diet: 7.0). In the highest dose group of HMT, the percentage of stillborn pups was 
higher than in the other groups (10 stillbirths out of 56 pups compared to four stillbirths out of 60 
control pups), due to the fact that only two pups in one litter of nine pups were born alive. No skeletal 
or  any  other  malformation  was  recorded  in  any  of  the  stillborn  pups.  During  the  first  month  a 
retardation of growth and an increase in mortality were noted in the highest dose of HMT no data 
provided).  In the same group the percentage of pups surviving to weaning was lower than in the other 
groups (33 out of 46 pups survived compared to 49 out of 56 control pups). At both dose levels of 
HMT, birth weight (equal to 90-92% of control pup birth weights) and post-natal growth (equal to 91-
94% of control pup weights in the 8
th week) were slightly decreased. All dogs observed for a longer 
period were reported to be normal in behaviour and general appearance. No malformations were found Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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in dogs observed up to 9 months. 18 other dogs transferred to the breeding colony and observed for 
nearly  2  years  did  not  show  any  signs  of  physiological  or  skeletal  abnormalities  or  disorders  of 
reproduction (Hurni and Ohder, 1973). Based on these data, the BAuA identified a NOAEL of 15 mg 
HMT/kg bw/day. Previously, the 1974 JECFA evaluation (JECFA, 1974) established an ADI based on 
this reproduction study where a NOEL value of 15 mg HMT/kg bw was specified for HMT (JECFA, 
1974;  TemaNord,  2002).  The  Panel  noted  that  the  EPA  evaluation  considered  that  there  were  a 
number of inconsistencies in the dog data which precluded their use. 
Studies on reproductive and developmental toxicity in humans are described briefly below. 
Pregnant women (206) who suffered from asymptomatic bacteriuria were studied in a systematic trial 
over a 2-year period and given doses equivalent to 29 mg methenamine hippurate/kg bw/day (70 
patients) or 57 mg methenamine mandelate/kg bw/day (69 patients) or no treatment (67 patients).  
Mean birth weights and gestation lengths showed no significant difference from the control group. In 
addition, the number of abortions, intrauterine deaths and fetal abnormalities in the treated groups did 
not differ from those of the general population (Furness et al., 1974). 
In a surveillance study involving 229 101 completed pregnancies, 8 (3.8 %) of the the newborns 
whose mothers had been treated with HMT during the first trimester had major birth defects (Briggs et 
al., 1994). 
In another study, no congenital abnormalities were observed in the children of 3 women who had 
taken  HMT  as  well  as  5  other  drugs  (choleinic  sidium,  phenolphthalein,  papaverine  HCL, 
methylhomatropine, and menthol) during the first two weeks of pregnancy (Siffel & Czeisel, 1995). 
In conclusion, a large set of data have been described on the reproductive and developmental toxicity 
of HMT in rats, dogs, and human. Overall, the information available is limited, due to the use of low 
numbers  of animals, limited number  of reproductive and developmental  parameters recorded, and 
teratogenicity not properly assessed. However, data available indicated that HMT did not present the 
potential to induce adverse effects on the fertility in rats.  Both the EPA (EPA, 2006) and the BAuA 
evaluations  (BAuA,  2008)  considered  a  NOAEL  of  1.5-2.5  g  HMT/kg  bw/day  for  reproductive 
toxicity  in  rats,  based  on  the  study  by  Della  Porta  et  al.  (1970).  With  regards  to  developmental 
toxicity, in both rats and beagle dogs adverse developmental effects observed during the postnatal 
period were preweaning mortality and postnatal growth retardation. The BAuA evaluation (BAuA, 
2008) reported NOAEL  values for developmental  toxicity for rats (Natvig et al., 1971)  and dogs 
(Hurni and Ohder, 1973) of 100 mg HMT/kg bw/day (the highest dose) and 15 mg HMT/kg bw/day, 
respectively. However, the EPA (2006) evaluation concluded that there are many inconsistencies on 
the results of the dog study, since the effects were not consistent with the dose levels, and no details 
have been provided to clarify these inconstancies. Therefore, the EPA (2006) did not take into account 
the dog study for their risk assessment (only the rat studies by Della Porta, 1970 and Berglund, 1966). 
In humans, the study by Furness et al. (1974) showed that no treatment-related abnormalities during 
the pregnancy or the development of the children had been reported. Negative findings were also 
found in the study by Siffel and Czeisel (1995). However, in the surveillance study by Briggs et al. 
(1994), 3.8% (of 209 newborn whose mothers had been treated with HMT during the first trimester) 
showed birth defects (BAuA, 2008). The BAuA evaluation (2008) concluded that, overall, all the 
studies reported did not sufficiently meet the requirements for a sound risk assessment evaluation with 
respect to reproductive and developmental toxicity. Overall, due to the limited value of the animal data 
BAuA proposed basing a quantitative risk assessment for developmental toxicity on the human data 
(NOAEL 27 mg HMT/kg bw/day) (BAuA, 2008). 
The  EFSA  Opinion  (EFSA,  2006)  on  formaldehyde  reported  that  formaldehyde  does  not  affect 
reproduction or gestational developmental parameters (IPCS, 1989; CICAD, 2002). Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
 
EFSA Journal 2014;12(6):3696  28 
3.2.6.  Hypersensitivity 
Guinea pigs exhibited strong skin sensitization in a maximization test with a 50% aqueous of HMT 
solution (Degussa et al., 1985). In a Local Lymph Node Assay (LLNA) a positive effect concentration 
(EC3) of 30.6% HMT was derived. A comparably low EC3 for formaldehyde was determined in the 
same  study  (De  Jong  et  al.,  2007).  Thus,  it  may  be  concluded  also  for  skin  sensitization,  that 
formaldehyde, which may be generated by hydrolysis of HMT in contact to skin, and not HMT, is the 
main causative agent of sensitization. 
The TemaNord evaluation (TemaNord, 2002) reported that there are several studies on the irritating 
and sensitising effects of HMT on the skin and the respiratory tract after occupational exposure in 
humans (TemaNord, 2002). HMT was shown to be non-sensitising to guinea pigs (TemaNord, 2002). 
The BAuA evaluation (BAuA, 2008) described that a number of cases of allergic symptoms such as 
wheezing and asthma were reported upon exposure to HMT (Gelfand, 1963). However, in all these 
cases  exposure  to  other  chemicals  occurred  simultaneously,  and  therefore  the  respiratory 
hypersensitivity could not specifically be attributed to HMT exposure. In another more recent study, 
respiratory  sensitization  (occupational  asthma)  after  occupational  exposure  to  HMT  could  not  be 
demonstrated.  However, irritant dermatitis of the hands in subjects with high exposure to HMT was 
found (Merget et al., 1999). 
3.2.7.  Other studies 
3.2.7.1.  Human studies  
The BAuA evaluation (BAuA, 2008) reported that HMT has been used in humans for many years as 
urinary antibacterial-antiseptic drug as well as for long-term prophylaxis of urinary tract infections. 
The bactericidal effect of HMT has been linked to its pH- and time-dependent hydrolysis in the urine 
to  ammonia  and  formaldehyde.  Therefore,  the  effectiveness  of  HMT  depends  on  an  adequately 
maintained urine concentration of formaldehyde, which in turn depends on the pH of the urine (pH 
<5.5), an increased fluid intake and high urine output, and the duration that urine is retained in the 
bladder (BAuA, 2008). The combination of HMT with acid salts (hippurate and mandelate) helps to 
maintain the urinary pH in the desired range (BAuA, 2008). 
The BAuA evaluation (BAuA, 2008) described that adverse effects occurred in less than 3.5% of 
patients receiving HMT or its salts. The most frequent adverse effects noted were nausea, vomiting, 
diarrhoea, abdominal cramps, and anorexia. Rarely, hypersensitivity reactions such as rash, pruritus, 
urticaria  and  stomatitis  have  occurred.  Other  less  frequently  reported  side  effects  were  headache, 
dyspnoea, generalized oedema, tinnitus, muscle cramps, dysuria, and microscopic or gross haematuria.  
High therapeutic doses of 8 g HMT/day (corresponding to 114 mg/kg bw/day based on a body weight 
of 70 kg) administered for 3 to 4 weeks induced bladder irritation, painful and frequent micturition, 
albuminuria  and  haematuria.  Other  adverse  effects  noted were  gingivitis,  anorexia,  headache,  and 
generalized  oedema.  No  complications  were  observed  in  patients  receiving  HMT  in  the  standard 
treatment for acute cystitis at dose levels of 2 to 4 g/day (corresponding to about 28 to 57 mg/kg 
bw/day based on a body weight of 70 kg) for a 7- to 10-day course up to four weeks. No adverse 
effects were observed in patients receiving HMT as an antiseptic at dose level of 4 to 6 g/day for 
weeks. HMT is also used for long-term suppressive therapy or for prevention of recurrent urinary 
infections. In long-term treatment with HMT and its salts (6 months or longer) at the usual oral dose of 
2-4 g/day (corresponding to 28-57 mg/kg bw/day based on a body weight of 70 kg) no relevant side 
effects were reported (BAuA, 2008). 
Other studies on the effects of HMT on humans following occupational exposure (by inhalation or 
skin contact) have been reported in the BAuA evaluation (BAuA, 2008). However, toxic effects in 
humans  at  the  workplace  have  only  been  reported  after  repeated exposure  to  mixtures  of  several 
compounds in addition to HMT such as formaldehyde, ammonia, resorcinol, phenol, furfuryl alcohol, 
cyanides, and epoxy resins, curing agents. There are also some reports describing lung and bladder Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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cancer in occupationally exposed workers in the steel foundry, tyre and rubber industries. However, 
considering the lack of measurements of HMT concentrations in the blood, urine, exhaled breath, or 
other biological media from exposed workers, the available occupational exposure studies were not 
adequately  designed  to  make  qualitative  assessments  of  the  observed  effects  in  relation  to  HMT 
exposure alone (BAuA, 2008). 
Overall,  these  available  human  data  did  not  provide  any  conclusive  information  on  any  potential 
association between occupational HMT exposure and cancer in humans. With regards to the use of 
HMT as a drug in humans there is no information available on the formation of tumours in the urinary 
tract or in other organs or tissues (BAuA, 2008). 
4.  Discussion 
The ANS Panel was not provided with a newly submitted dossier and based its evaluation on previous 
evaluation, reviews and additional literature that became available since then. An additional source of 
information was the registration dossier provided by industry for HMT under the REACH Regulation 
1907/2006, published by the European Chemicals Agency (ECHA, 2011). The Panel noted that not all 
original studies on which previous evaluations or reviews were based were available for re-evaluation 
by the Panel. 
Specifications for HMT have been defined in Commission Regulation (EU) No 231/2012 and by 
JECFA (2006).  HMT is described as colourless or white crystalline powder.  The purity is specified 
as not less than 99% anhydrous.  Under acidic aqueous conditions HMT can yield formaldehyde and 
ammonia. 
HMT (E 239) is currently only permitted for use in Provolone cheese at a maximum level of 25 mg/kg 
residual  amount,  expressed  as  formaldehyde.  The  formaldehyde  released  from  HMT  under  acidic 
conditions or in cheese can react with proteins. 
HMT has been previously evaluated by the Joint Expert Committee on Food Additives (JECFA) in 
1962, 1965, 1967, 1972 and 1974 (JECFA, 1962, 1965, 1967, 1972 and 1974). JECFA established an 
ADI of 0.15 mg/kg bw/day based on a reproductive study with a NOEL of 15 mg/kg bw/day (JECFA, 
1974). HMT has not been directly evaluated as a food additive by the Scientific Committee on Food 
(SCF). In 1977, the SCF referred to HMT during its evaluation of the use of formaldehyde in grana 
padano  cheese,  since  HMT  decomposes  to  form  formaldehyde  under  acidic  conditions  or  in  the 
presence of proteins (SCF, 1977). More recently, TemaNord in 2002 (TemaNord, 2002), the United 
States  Environmental  Protection  Agency  (EPA)  in  2006  (EPA,  2006),  the  Federal  Institute  for 
Occupational Safety and Health (BAuA, Germany) in 2008 (BAuA, 2008) reviewed the safety of 
HMT. 
In humans, about 88% of an oral dose of HMT was absorbed within 12 hours and excreted mostly 
unchanged (about 82% of recovery) in the urine in 24 hours (BAuA, 2008). The maximum serum 
concentration (35.2 mg/L) after a single dose was achieved within 1 hour and the mean elimination 
half-life in blood was reported to be 4.3 hours. Approximately 10-20% of an oral dose of HMT is 
converted to formaldehyde prior to absorption. HMT can pass the placenta and is detectable in breast 
milk of breastfeeding women; however, no accumulation was reported. Since, formaldehyde formation 
from  HMT  is  strongly  dependent  on  acidic  pH  values,  formaldehyde  generation  is  only  relevant 
following oral ingestion as the pH of the stomach is acidic. Further down the gastrointestinal tract, the 
pH  is  neutral  with  nearly  no  generation  of  formaldehyde  (BAuA,  2008).    However  when  used 
therapeutically HMT is intended to break down to formaldehyde in the urinary tract and compounds 
which  lower  urinary  pH  are  often  co-administered.  Since  it  has  been  shown  that  under  acidic 
conditions,  HMT  is  converted  to  formaldehyde,  which  in  turn,  is  converted  into  formic  acid, 
toxicokinetic  information  on  formaldehyde  and  its  metabolite  formic  acid  is  relevant  for  the  risk 
characterisation of HMT. Overall, both in animal and human studies formaldehyde is rapidly absorbed 
and converted to formic acid. The rate of oxidation of formaldehyde to formic acid was comparable in Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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all animal species, with a half-life of only 1 minute. The elimination half-life of formic acid varies 
from 55 minutes in animals (mainly studied in rodents) to 90 minutes in humans with excretion via the 
kidneys or further oxidation to carbon dioxide and water (JECFA 1962, 1965, 1972, 1974; BAuA, 
2008). 
Results from animal experiments and limited data in humans indicate that HMT is of very low to 
moderate acute toxicity. 
There are limited studies available on the subchronic toxicity of HMT. None of the studies provided 
data on haematology and clinical chemistry; data on histopathology were limited. However, body 
weight gain, food consumption, survival, organ weights, gross pathology and histopathology were 
generally unaffected following exposure to HMT. The only treatment related clinical observation was  
a yellow staining of the perineal hair in some cases in studies with rats and decreased body weight 
gain or weight loss in one 15-week study in rabbits (RTECS, 2005 as referenced by EPA, 2006). 
Spinacine, the most abundant end-product of formaldehyde in cheese (derived from the N-terminal 
histidine residue in gamma 2-casein) showed a NOAEL of 300 mg/kg bw/day in short term toxicity 
studies. The BAuA (2008) evaluation reported that the available repeated dose toxicity studies on 
HMT via oral administration (gavage, diet, drinking water) neither conformed to standard repeated 
dose toxicity testing protocols nor were performed according to currently accepted test guidelines. 
However,  BAuA  evaluation  considered  the  available  data  were  sufficiently  acceptable  to  derive 
NOAELs for repeated-dose oral toxicity (BAuA, 2008). The Panel agreed with this conclusion. 
With regards to the genotoxicity, HMT was weakly positive in bacterial gene mutation assays and in 
an indicator tests in yeast  and at high doses in tests for chromosomal aberrations and sister chromatid 
exchanges in  mammalian cells in vitro (BAuA,  2008). In vivo, negative results were  obtained in 
chromosomal aberration tests in mouse bone marrow by the oral route and in the dominant lethal test 
in mice by i.p. administration.(BAuA, 2008), indicating that the genotoxic activity elicited by HMT in 
vitro is not systemically expressed in vivo. The Panel noted that HMT may be partially converted in 
the stomach into formaldehyde which, at high doses, is genotoxic in vivo at the site of first contact. In 
this respect the Panel noted that HMT used as food additive breaks down into formaldehyde during 
cheese-making and storage, and that in situ formed formaldehyde largely reacts with amino groups of 
milk proteins. Thus, the exposure to formaldehyde resulting from the use of HMT as food additive is 
expected  to  be  negligible,  much  lower  than  resulting  from  other  authorized  uses  or  from  normal 
mammalian metabolism (878-1310 mg/kg bw per day assuming a half -life of1-1.5 min; EFSA, 2014). 
Overall, the Panel concluded that the proposed use of HMT as food additive does not raise concern for 
genotoxicity. 
The  Panel  noted  that  human  therapeutic  use  of  HMT  would  result  in  much  higher  levels  of 
formaldehyde generated in the stomach and in the urinary tract than from its use as a food additive. 
The Panel noted that HMT is limited to a single use in the EU and taking into account the estimated 
maximum exposure to formaldehyde from this use, considered that the available data were sufficient 
for this restricted use. However HMT can be converted into formaldehyde at the acidic pH of the 
stomach. Given the high reactivity of formaldehyde, as highlighted by the information summarized 
below, it is conceivable that genotoxicity of HMT-generated formaldehyde would only be detectable 
at the site of contact. Thus, the Panel noted that further in vivo testing in stomach as target tissue 
would be required to adequately assess the genotoxic potential of orally ingested HMT. The Panel 
concluded that this would be a priority if the uses or use levels of HMT were to increase but no 
information is available for local effects on the gastrointestinal tract. 
Available studies on the chronic toxicity of HMT are limited.  None of the studies provided data on 
haematology and clinical chemistry. However, body weight gain, food consumption, organ weights, 
gross pathology and histopathology were unaffected following exposure to HMT. However, survival 
rates and growth were significantly decreased in a study in CTM mice treated with 12.5 g HMT/kg 
bw/day HMT for 30 weeks. The only treatment related clinical observation in studies with rats was Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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occasional yellow staining of the perineal hair. Overall, the data available do not indicate a potential 
for HMT to be carcinogenic in experimental animals at dosages up to 2.5 g HMT/kg bw/day (Brendel, 
1964;  Natvig  et  al.,  1971;  Della  Porta,  1968;  Lijinsky  and  Taylor,  1977).  However,  the  JECFA 
evaluation  (1972)  reported  benign  and  malignant  tumours  in  mice  fed  1%  HMT  or  0.15% 
formaldehyde for 2 years (Kewitz, 1966). For all the studies, the NOAELs for HMT corresponded to 
the  highest  dose  tested.  The  BAuA  (2008)  evaluation  reported  that  the  existing  long-
term/carcinogenicity studies on HMT were not in line with the current guidelines on carcinogenicity 
and/or combined chronic toxicity/carcinogenicity. However, the data submitted were considered useful 
in assessing the carcinogenic potential of HMT (BAuA, 2008). In addition, considering the negative 
results  from  in  vivo  genotoxicity  testing,  BAuA  concluded  that  HMT  was  not  considered  as 
carcinogenic for experimental animals (BAuA, 2008). The BAuA evaluation (2008) also reported that 
one valid cancer study with formaldehyde administered via drinking water to rats did not show an 
increased tumour incidence in any organ (Til et al., 1989). Therefore, the BAuA evaluation (2008) 
concluded that the formation of formaldehyde from HMT should not be of concern with regards to 
carcinogenicity  (BAuA,  2008).  The  Panel  noted  that  there  are  other  studies  on  toxicity  of 
formaldehyde discussed in the EFSA opinion (2006). 
A large set of data have been described on the reproductive and developmental toxicity of HMT in 
rats, dogs, and human. Overall, the information available is limited, due to the use of reduced animal 
numbers, limited number of reproductive and developmental parameters recorded, and developmental 
parameters  not  properly  assessed.  However,  data  available  indicated  that  HMT  did  not  have  the 
potential to induce adverse effects on the fertility in rats.  Both the EPA (EPA, 2006) and the BAuA 
evaluations (BAuA, 2008) considered a NOAEL of 1 500-2 500 mg HMT/kg bw/day for reproductive 
toxicity in male and 2000-2 500 mg HMT/kg bw/day in female rats, based on the study by Della Porta 
et  al.  (1970).  With  regards  to  developmental  toxicity,  in  both  rats  and  beagle  dogs  adverse 
developmental effects observed during the postnatal period were preweaning mortality and postnatal 
growth  retardation.  The  BAuA  evaluation  (BAuA,  2008)  reported  NOAELs  for  developmental 
toxicity for rats (Natvig et al., 1971) and dogs (Hurni and Ohder, 1973) of 100 mg HMT/kg bw/day 
(the highest dose) and 15 mg HMT/kg bw/day, respectively. However, the EPA (2006) evaluation 
concluded that there are many inconsistencies on the results of the dog study, since the effects were 
not consistent with the dose levels, and no details have been provided to clarify these inconstancies. 
Therefore, the EPA (2006) did not take into account the dog study for their risk assessment (only the 
rat studies by Della Porta, 1970 and Berglund, 1966). In addition, the unpublished study by Kewitz 
(1966) reported that 66.7% of the HMT-treated dogs (30 litters) were considered unusual in having 
stillborn pups and cannibalism, as well as 5 cases of animals born were reported with malformation 
(JECFA,  1972).  In  humans,  the  study  by  Furness  et  al.  (1974)  showed  that  no  treatment-related 
abnormalities during the pregnancy or the development of the children had been reported. Negative 
findings were also found in the study by Siffel and Czeisel (1995). However, in the surveillance study 
by Briggs et al. (1994), 3.8% of 209 newborn treated with HMT during the first trimester, showed 
birth defects (BAuA, 2008). The BAuA evaluation (2008)  concluded that,  overall,  all the studies 
reported do not sufficiently meet the requirements for a sound risk assessment evaluation with respect 
to  reproductive  and  developmental  toxicity.  The  Panel  concluded  that  despite  limitations  in  the 
database on reproductive and developmental toxicity, the available data were sufficient for evaluating 
the single permitted use and use levels. 
No adverse effects have been reported in patients receiving HMT for long-term prophylaxis or therapy 
as urinary antibacterial-antiseptic substance at dose levels of 2 to 4 g/day (corresponding to 28 to 57 
mg/kg bw/day) for up to 4 weeks (corresponding to a NOAEL of 57 mg/kg bw/day). However, with a 
higher dose of 8 g/day (corresponding to 114 mg/kg bw/day) over 3 to 4 weeks clinical symptoms 
such as bladder irritation, painful and frequent micturition, albuminuria and haematuria were reported 
in some individuals (BAuA, 2008). With regards to the use of HMT as a drug in humans there is no 
information available on the formation of tumours in the urinary tract or in other organs or tissues 
(BAuA, 2008). In humans, skin sensitizing properties of HMT have been reported. Following skin 
contact acute dermatitis was the main symptom. Other reports described a number of cases in which 
allergic symptoms of the respiratory system were also reported following HMT exposure. However, in Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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all cases exposure to other chemicals occurred simultaneously, therefore the induction of specific 
respiratory hypersensitivity by HMT cannot be clearly demonstrated (BAuA, 2008). Regarding data 
available  on  effects  of  HMT  on  human  following  occupational  exposure  (by  inhalation  or  skin 
contact), human data available do not provide any conclusive information on the association between 
HMT exposure and cancer in humans, since toxic effects in humans at the workplace have only been 
reported after repeated exposure to mixtures of several compounds rather than HMT alone (BAuA, 
2008).  
Although there are limitations in the toxicological database overall an assessment of the risks can be 
made. The available database indicates that whilst HMT demonstrates genotoxic potential in vitro, this 
is not expressed in vivo. In chronic toxicity and carcinogenicity studies in rodents reported NOAELs 
were generally the highest dose tested, however the studies were old and not performed according to 
current standards. There is an extensive database on reproductive toxicity but the studies are poorly 
reported. JECFA based its ADI on the NOAEL of 15 mg/kg bw/day from a developmental toxicity 
study in dogs. The Panel noted however that more recent evaluations by EPA and BAuA have not 
considered  this  study  an  adequate  basis  for  establishing  health  based  guidance  values.  The  Panel 
considered that the limitations in the toxicological database meant that it was not possible to clearly 
identify the critical study and therefore no NOAEL could be identified as relevant Point of Departure 
(POD) for derivation of an ADI. 
In  humans  no  adverse  reactions  were  reported  following  doses  up  to  4  g  HMT/day  for  4  weeks 
(equivalent to 57 mg HMT/kg bw/day). 
At therapeutic doses the majority of the dose is excreted into urine as HMT but is intended to release 
formaldehyde under acidic conditions in the urinary tract. A significant portion of the dose (10-20%) 
produces formaldehyde systemically. HMT has a relatively short half-life. It appears that at high doses 
the rate of conversion to formaldehyde is insufficient to prevent urinary excretion of the bulk of the 
dose as HMT. However this might not apply at lower doses. 
The estimated mean exposure to HMT (expressed as formaldehyde) via consumption of Provolone 
cheese was low for the total population: on average 0.3 µg formaldehyde/kg bw/day (Table 4). For 
consumers only of Provolone cheese the mean exposure ranged from 5 µg formaldehyde/kg bw/day in 
toddlers up to 20 µg formaldehyde/kg bw/day in children (95
th percentiles: 18 µg formaldehyde/kg 
bw/day for adults). If it was assumed that all ripened cheese consumed was Provolone cheese, the 
highest estimated exposure, using the 95
th percentile of consumers only combined with the MPL, 
equalled 87 µg formaldehyde/kg bw/day in children. 
The Panel noted that in acidic conditions HMT broke down with the formation of formaldehyde which 
would then be metabolised to formic acid. The Panel noted and endorsed the conclusions of the 2006 
EFSA evaluation of formaldehyde. The Panel considered that given the current limited permitted use 
of HMT and assuming formaldehyde was at the maximum residual levels, the highest exposure via the 
consumption of Provolone cheese would be 20 µg formaldehyde /kg bw/day in children, this exposure 
is unlikely to represent a safety concern. The Panel is, however, aware that this exposure level is a 
mean exposure estimate and that the exposure in this age group could potentially be higher. Due to 
lack of food consumption data this high exposure could however not be calculated for this population 
group.  The  high  exposure  that  could  be  calculated  was  for  the  adults  and  lower  than  the  mean 
exposure  in  children  (18  µg  formaldehyde  /kg  bw/day).  Assuming  that  all  cheese  consumed  is 
Provolone cheese a theoretical conservative assumption of intake of HMT expressed as formaldehyde 
could be calculated of 87 µg/kg bw day. Also this level is however unlikely to represent a safety 
concern. 
The theoretical conservative assumption of intake of HMT in children of 87 µg formaldehyde/kg 
bw/day would result in a plasma steady state concentration of 0.25 µM and a peak concentration of 1.5 
µM for formaldehyde/formaldehyde acetal. The increase in formaldehyde acetal associated with an 
exposure to HMT at the currently permitted uses and use levels, expressed as formaldehyde residual Re-evaluation of hexamethylene tetramine (E 239) as a food additive 
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levels (and if ingested as a single dose which then formed a formaldehyde acetal with water),, would 
be less than 0.07 % (for the steady state level) and less than 0.38 % (for the peak level) of the normal 
intracellular  endogenous  levels  (EFSA  ANS  Panel,  2013;  EFSA,  2014).  Such  additional  burden  
should be evaluated in the light of the naturally occurring inter-species and intra-species variation in 
the  internal  level  of  methanol,  formaldehyde  and  formaldehyde  acetal  which  by  far  exceed  the 
difference between internal concentration of  these endogenous substances and the additional exposure 
by oral intake to HMT at the currently permitted uses and use levels. Kleinnijenhuis et al. (2013) using 
a  sensitive  and  specific  method  have  measured  a  formaldehyde  concentration  in  blood  of  2.25 ± 
0.67 mg/L in rats. This corresponds to a coefficient of variation of 30 % in endogenous formaldehyde 
blood  levels  in  rats.  Thus,  the  Panel  concluded  that  the  additional  ammonium  and  formaldehyde 
arising from HMT at the currently permitted use and use levels (expressed as formaldehyde residual 
levels) does not constitute a significant additional risk above the risk given by the naturally occurring 
endogenous ammonium and formaldehyde, even when worst case  assumptions are used. 
CONCLUSIONS AND RECOMMENDATIONS 
The Panel concluded that due to the limitations in the toxicological database a critical study could not 
be identified and therefore it was not possible to derive an ADI. The exposure to formaldehyde from 
HMT of high level consumers (95
th) of Provolone cheese equalled 18 µg formaldehyde/kg bw/day in 
adults and could be as high as 87 µg formaldehyde/kg bw/day in 3-9 year old children according to a 
theoretical conservative assumption that all ripened cheese consumed was Provolone cheese. These 
exposures were around 1000 fold lower than formaldehyde exposure corresponding to the human 
therapeutic doses of 57 HMT mg/kg bw/day not associated with adverse effects in humans. Based on 
the:  
  estimated exposures,  
  consideration of the overall toxicological database on HMT,  
  oral toxicity and toxicokinetic data of formaldehyde,  
  the magnitude of the potential effect on intracellular formaldehyde levels arising from this use 
of HMT  
the Panel concluded that the  use of HMT in Provolone cheese at the MPL of 25 mg/kg residual 
amount, expressed as formaldehyde, would not be of safety concern. 
However the Panel considered that any increase in the permitted uses of HMT or increases in the MPL 
of 25 mg /kg residual amount, expressed as formaldehyde would require detailed assessment which 
might  require  new  toxicity  data  as  well  as  use  levels  and/or  an  evaluation  of  its  impact  on 
formaldehyde levels in vivo. 
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ABBREVIATIONS 
ADME  Absorption, Distribution, Metabolism and Excretion 
ADI  Acceptable Daily Intake 
bw  Body weight 
CAS  Chemical Abstract Service 
Chem Id Plus  A free database of 350000 chemical compounds 
EC  The European Committee 
EFSA  The European Food Safety Authority 
EINECS  European  Inventory  of  Existing  Commercial  chemical 
Substances 
EU  The European Union 
FAO  The Food and Agriculture Organisation of the United Nations 
IARC  International Agency for Research on Cancer 
JECFA  The FAO/WHO Joint Expert Committee on Food Additives 
TemaNord  Nordic  Working  Group  on  Food  Toxicology  and  Risk 
Assessment 
NOEL  No Observed Effect Level 
SCF  The EU Scientific Committee on Food 
US EPA  The US Environmental Protection Agency 
WHO  The World Health Organisation 
 